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1 Introduction 
1.1 Mechanisms of mitochondrial homeostasis 
In eukaryotic cells, mitochondria fulfill a multitude of essential functions, ranging from 
energy production to mediating apoptotic cell death. Thus, cells employ a sophisticated 
system of organelle-specific molecular chaperones and proteases to maintain 
mitochondrial biogenesis and protein quality control (PQC) under normal and stress 
conditions. These processes collectively contribute to mitochondrial protein homeostasis. 
On the one side, mitochondrial chaperones of the Hsp60 and Hsp70 type assist import and 
folding of nuclear-encoded proteins, which constitute the fast majority of the 
mitochondrial proteome. On the other side, these chaperones work together with 
specialized soluble and membrane-associated proteases to prevent the accumulation of 
damaged or superfluous proteins through refolding or degradation (Voos, 2013). In 
particular under intrinsic or externally imposed stress conditions, the biochemical 
mechanisms of mitochondrial PQC may be exhausted. The resulting accumulation of 
denatured or even aggregated polypeptides constitutes a severe danger for mitochondrial 
and cellular health. Apart from the loss of important metabolic functions, damaged 
mitochondrial may exert a negative influence on cellular survival by releasing large 
amounts of reactive oxygen species (ROS) or apoptotic proteins including cytochrome c 
(Andersen & Kornbluth, 2013, Halliwell, 2006). Thus, cells possess an additional 
mechanism of organellar quality control. This process, which utilizes the reactions of 
cellular autophagy to remove irrevocably damaged mitochondria as a whole, is termed 
mitophagy. At the beginning of a putative signaling pathway, arguably deciding about 
“life or death” of defective mitochondria, stands the mitochondrial kinase Pink1 (Ashrafi 
& Schwarz, 2013). The question, how Pink1 signals mitochondrial damage and which 
events lead to its activation has been addressed in the present work. 
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1.2 Mitochondrial dysfuction in Parkinsons’s disease 
Over the last years, mitochondrial dysfunction has emerged as a common feature of aging-
related neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease or amyotrophic lateral sclerosis (ALS) (Lin & Beal, 2006). With a 
prevalence estimated at 0.3 % of the entire population and 1 % in people over the age of 
60, Parkinson’s disease (PD) is the second most common neurodegenerative disorder (de 
Lau & Breteler, 2006). PD is clinically characterized by four key symptoms: rigidity, 
postural instability, tremor and a typical slowness in executing movements termed 
bradykinesia. These neurological symptoms are collectively caused by the progressive loss 
of dopaminergic neurons in the substantia nigra pars compacta (Lang & Lozano, 1998a, 
Lang & Lozano, 1998b). 
 
First evidence for a link between Parkinson’s disease and mitochondria dates back to the 
late 1970s, when accidental exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a synthesis byproduct of the illegal drug 1-methyl-4-phenyl-4-propionoxy-
piperidine (MPPP) was shown to cause PD-like symptoms and degeneration of 
dopaminergic neurons (Langston, Ballard et al., 1983). MPTP was later demonstrated to 
be oxidized to MPP+, which is selectively taken up by dopaminergic neurons via the 
dopamine transporter (Javitch & Snyder, 1984), and inhibits complex I of the 
mitochondrial respiratory chain (Nicklas, Vyas et al., 1985). Accordingly, a similar effect 
results from exposure to complex I inhibitors like rotenone or paraquat, developed as 
pesticide and herbicide, respectively. Both chemicals cause Parkinsonism in animal 
models (Berry, La Vecchia et al., 2010, Betarbet, Sherer et al., 2000). A second line of 
evidence for the exceptional role of mitochondria in the etiology of PD comes from 
mutations in the mitochondrial genome (mtDNA). The 16,500 base pairs comprising 
circular mtDNA encodes 13 genes for subunits of respiratory chain complexes I, III, IV 
and V along with 22 mitochondrial tRNAs and two rRNAs, respectively (Anderson, 
Bankier et al., 1981). High levels of large-scale somatic mtDNA deletions, causing 
mitochondrial dysfunction, were found in substantia nigra neurons from post-mortem 
brains of PD patients (Bender, Krishnan et al., 2006). Moreover, patients with mutations in 
the mitochondrial polymerase γ accumulate excessive levels of mtDNA mutations as a 
result of defective mitochondrial replication and this defect coincides with an increased 
risk for developing PD (Luoma, Melberg et al., 2004).  
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Table 1: Overview of PARK-designated Parkinson’s disease-related loci, mode of inheritance, gene 
names and names of encoded proteins. Bold: Loci linked to monogenic PD. AD: autosomal dominant, 
AR: autosomal recessive. Asterisk: erroneous locus (identical to PARK1). Modified after (Klein & 
Westenberger, 2012). 
Symbol Inheritance Gene name Protein name 
(short name) 
UniProt 
entry 
number 
PARK1 AD SNCA Alpha-synuclein P37840 
PARK2 AR PARKN E3 ubiquitin-protein ligase 
parkin 
(Parkin) 
O60260 
PARK3 AD unknown unknown - 
PARK4* AD SNCA Alpha-synuclein P37840 
PARK5 AD UCHL1 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 
(UCH-L1) 
P09936 
PARK6 AR PINK1 Serine/threonine-protein 
kinase Pink1, mitochondrial 
(Pink1) 
Q9BXM7 
PARK7 AR DJ-1 Protein-deglycase DJ-1 
(DJ-1) 
Q99497 
PARK8 AD LRRK2 Leucine-rich repeat 
serine/threonine- protein 
kinase 2  
(LRRK2) 
Q5S007 
PARK9 AR ATP13A2 Probable cation-transporting 
ATPase 13A2 
Q9NQ1 
PARK10 risk factor unknown - - 
PARK11 AD unknown - - 
PARK12 risk factor unknown - - 
PARK13 AD or risk 
factor 
HTRA2 
OMI 
Serine protease HtrA2, 
mitochondrial 
(HtrA2/Omi) 
O43464 
PARK14 AR PLA2G6 85/88 kDa calcium-
independent phospholipase 
A2 
(CaI-PlA2) 
O60733 
PARK15 AR FBX07 F-box only protein 7 Q9Y3I1 
PARK16 risk factor unknown - - 
PARK17 AD VPS35 Vacuolar protein sorting-
associated protein 35 
 (hVPS35) 
Q96QK1 
PARK18 AD EIF4G1 Eukaryotic translation 
initiation factor 4 gamma1 
(eIF-4G1) 
Q04637 
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While about 90 % of PD cases are sporadic, studying the rare hereditary cases has led to 
the identification of several genes contributing to onset and progress of Parkinson‘s 
disease. The 18 loci demonstrated or suspected to relate to the disease shown in Table 1, 
were termed PARK and numbered chronologically in order of their identification (Klein & 
Westenberger, 2012).  
 
In brief, six genes are linked to monogenic PD, meaning a form of the disease for which a 
mutation in a single gene is sufficient to cause the phenotype. Among them is SNCA 
(PARK1), encoding α-synuclein. Point mutations in the α-synuclein-encoding gene SNCA 
as well as gene duplications or triplications, respectively, have been shown to cause PD 
(Klein & Westenberger, 2012). The 140 aa α-synuclein protein is the major component of 
the so-called Lewy bodies. These intraneuronal proteinaceous inclusions are the 
morphological characteristic of PD and related diseases, summarized as 
α-synucleinopathies (Goedert, 2001). In Lewy bodies, which represent insoluble deposits 
of the protein, α-synuclein is present in fibrils with a β-sheet like structure (Der-
Sarkissian, Jao et al., 2003). It is thought that the pathogenicity of the aggregation-prone 
α-synuclein involves the formation of small neurotoxic oligomers, which eventually 
mature to larger aggregates (Haass & Selkoe, 2007). In addition to its predominantly 
cytosolic localization, α-synuclein has been proposed to localize at or in mitochondria 
(Devi, Raghavendran et al., 2008, Li, Yang et al., 2007). Functional links between the 
protein and mitochondria stem from the observation, that mutant α-synuclein sensitizes 
neurons to mitochondrial toxins like MPP+. Moreover, effects of α-synuclein on 
mitochondrial dynamics, meaning the fusion and fission of mitochondria, have been 
reported (Nakamura, 2013). Another gene accountable for monogenic PD is DJ-1 
(PARK7). The DJ-1 protein is sensitive to oxidative stress and may act as a redox-
responsive chaperone, which can prevent protein misfolding (Shendelman, Jonason et al., 
2004). Notably, DJ-1 was found to reloaclize to mitochondria in the presence of reactive 
oxygen species (Canet-Aviles, Wilson et al., 2004) and mitochondrial defects were 
observed in DJ-1-deficient Drosophila and mouse models (Hao, Giasson et al., 2010). 
Mutations in PARK8, encoding the serine/threonine kinase LRRK2, are the most common 
cause of autosomal dominant PD (Klein & Westenberger, 2012). LRRK2 interacts with 
regulators of mitochondrial fusion and fission. Accordingly, PD-related mutations of the 
protein alter mitochondrial dynamics (Ryan, Hoek et al., 2015). Intriguingly, LRRK2 
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inhibits the removal of proteins by chaperone-mediated autophagy (CMA), leading to 
accumulation of CMA substrates, including α-synuclein (Orenstein, Kuo et al., 2013). 
Through this mechanism, LRRK2 may contribute to α-synuclein aggregation and 
α-synuclein-dependent mitochondrial damage (Ryan et al., 2015) HTRA2 (PARK13) 
encodes the stress-inducible mitochondrial serine protease HtrA2 (Omi), which resides in 
the intramembrane space. Proteins of the HtrA family have the remarkable property to 
switch between protease and chaperone activity. It is speculated that the mitochondrial 
HtrA2 functions in protein quality reactions, comparable to the bacterial HtrA homologs, 
including DegP. However, clear evidence for a role of HtrA2 in PQC is lacking so far 
(Voos, 2013). Moreover, upon apoptotic stimuli, HtrA2 is released into the cytosol to 
promote apoptosis (Vande Walle, Lamkanfi et al., 2008). Loss-of-function mutations, 
affecting the regulation of the proteolytic activity of HtrA2 were identified in the HTRA2 
gene from heterozygous PD patients (Strauss, Martins et al., 2005). Finally, mutations in 
two genes, encoding the mitochondrial serine/threonine-protein kinase Pink1 (PARK6) 
and the cytosolic E3 ubiquitin-protein ligase Parkin (PARK2), respectively, cause 
autosomal recessive PD (Kitada, Asakawa et al., 1998, Valente, Abou-Sleiman et al., 
2004). Pink1, which collaborates with Parkin to mediate the removal of damaged 
mitochondria by mitophagy, has been in the focus of this work.  
 
In summary, out of the six gene products associated with monogenic PD, five are linked to 
mitochondrial function and at least one additional mitochondrial protein may contribute to 
the etiology of the disease. Thus, functional insight from PD-related proteins strongly 
supports prior evidence for a role of mitochondrial dysfunction in Parkinson’s disease. 
 
1.3 Identification of Pink1 
Pink1 was initially identified in a screen for proteins transcriptionally regulated by the 
tumor suppressor PTEN (phosphatase and tensin homolog) and predicted to contain a 
highly conserved serine/threonine-protein kinase domain. Accordingly, the protein was 
termed PTEN-induced putative kinase 1 (Pink1) (Unoki & Nakamura, 2001). Further 
analysis revealed that Pink1 consists of 581 amino acids, with a predicted molecular mass 
of 62.8 kDa and is ubiquitously expressed, with highest expression in heart, skeletal 
muscle and testis (Unoki & Nakamura, 2001). Pink1 is conserved among eukaryotes 
ranging from C. elegans and D. melanogaster to humans but absent from the model 
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organism yeast. While a role in PTEN-signaling was excluded by Unoki et al., the protein 
gained major attention ever since mutations in the PINK1 (PARK6) gene affecting the 
Pink1 kinase domain, were shown to be responsible for hereditary early onset Parkinson’s 
disease (Valente et al., 2004). In the same study, and in agreement with a predicted 
mitochondrial targeting signal, Pink1 was demonstrated to localize to mitochondria. 
 
1.4 Import, processing and submitochondrial localization of 
Pink1 
Initial reports on the mitochondrial localization of Pink1 motivated further investigations 
regarding import and suborganellar localization of the protein. Like most mitochondrial 
proteins, Pink1 is encoded in the nuclear genome and synthesized at cytosolic ribosomes. 
In the classical presequence import pathway, a matrix-destined mitochondrial preprotein is 
directed to the cytosol-exposed receptors of the outer mitochondrial membrane by an N-
terminal mitochondrial targeting signal (MTS). Translocation across the outer- and inner 
membrane (OMM and IMM) then occurs via the TOM and TIM23 translocase complexes, 
respectively. Insertion of the preprotein into the TIM23 channel implicitly requires the 
presence of a mitochondrial membrane potential (Δψ), as the electrochemical gradient 
drives translocation of the positively charged targeting signal. Moreover, complete 
translocation of the polypeptide into the matrix is dependent on ATP hydrolysis by the 
import motor complex at the inner face of the inner membrane translocase complex. Upon 
crossing of the preprotein through the IMM, the targeting sequence is usually cleaved off 
by the matrix processing peptidase (MPP). This processing reaction gives rise to the 
mature protein, which is released into the matrix compartment. Apart from transport into 
the matrix, multiple other import pathways direct proteins to their specific mitochondrial 
subcompartment (Becker, Böttinger et al., 2012b).  
 
The very N-terminal segment of the Pink1 sequence resembles a mitochondrial targeting 
signal (Figure 1) (Valente et al., 2004), which was reported to be sufficient for 
mitochondrial localization of the protein (Silvestri, Caputo et al., 2005). Moreover, an 
N-terminal Pink1 processing product of apparently 55 kDa was identified in addition to 
the 64 kDa full-length Pink1 (Beilina, Van Der Brug et al., 2005). Although both 
observations theoretically agree with import of Pink1 into the mitochondrial matrix, a 
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more complex and partially controversial picture of Pink1 import and processing emerged 
from subsequent studies.  
 
 
Figure 1: Schematic representation of domain structure and cleavage sites within the Pink1 sequence. 
The N-terminal mitochondrial targeting signal is followed by a hydrophobic transmembrane domain, which 
comprises residues 85 to 110 and acts as an inner membrane stop-transfer signal. Residues 156 to 509 
constitute the Ser/Thr kinase domain, followed by a C-terminal domain, which may act as an OMM 
retention signal. Protease cleavage sites for MPP and PARL and the resulting Pink1 fragments are indicated. 
Note that the MPP cleavage site was estimated from the molecular mass of the MPP processing product.  
 
First, different submitochondrial localizations of Pink1 were reported, making it difficult 
to define an import pathway for the protein. While both full-length and processed Pink1 
are predominantly located at the outer face of the OMM with the kinase domain facing the 
cytoplasm (Becker, Richter et al., 2012a, Zhou, Huang et al., 2008), the protein was 
alternatively found in the intermembrane space (IMS) (Meissner, Lorenz et al., 2011) and 
in the IMM (Silvestri et al., 2005). In addition, a fraction of the processed Pink1 fragment 
was shown to localize to the cytosol (Lin & Kang, 2008). Secondly, a role of the 
mitochondrial membrane potential in import, localization and arguably stability of Pink1 
was proposed. While under basal conditions, endogenous Pink1 is barely, if at all 
detectable by Western blot or immunofluorescence (Becker et al., 2012a, Zhou et al., 
2008), the protein accumulates on mitochondria upon dissipation of Δψ (Jin, Lazarou et 
al., 2010, Narendra, Jin et al., 2010b). Thirdly, different proteases were demonstrated to 
sequentially process Pink1, possibly influencing its submitochondrial localization and 
suggesting a complex interplay of import and processing reactions (Deas, Plun-Favreau et 
al., 2010a, Greene, Grenier et al., 2012).  
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Using an in vitro assay, Becker et al. elucidated the mitochondrial import pathway of 
Pink1 in detail (Becker et al., 2012a). The results of the latter and other studies suggest 
that in the presence of an inner membrane potential, the Pink1 polypeptide is partially 
inserted into the IMM through the TOM and TIM23 complexes (Figure 2). An N-terminal 
hydrophobic segment adjacent to the presequence-like signal, acts as a stop-transfer 
signal, preventing full translocation of Pink1 over the IMM (Zhou et al., 2008). When the 
N-terminal portion reaches the matrix, it is cleaved by MPP, resulting in the formation of a 
60 kDa cleavage product (Pink1f60) (Greene et al., 2012). The IMM resident protease 
PARL (Presenilin-associated rhomboid-like protein) then catalyzes a second cleavage 
between positions 103 and 104 within the Pink1 sequence, generating a 53 kDa fragment 
(Pink1f53) (Deas et al., 2010a). Upon cleavage by PARL, the processed fragment is 
released from the import machinery. Pink1f53 then associates with the OMM via its very C-
terminal hydrophobic portion (Becker et al., 2012a). Pink1f53 was further demonstrated to 
be degraded by the proteasome, a process that would require its full translocation to the 
cytosol (Matsuda, Sato et al., 2010, Yamano & Youle, 2013). By contrast, in depolarized 
mitochondria, the 64 kDa full-length Pink1 (Pink1p64) associates with the OMM, possibly 
through binding of the presequence-like N-terminal segment of Pink1 to cytosol-exposed 
TOM receptors. As further translocation of Pink1 is arguably prevented in the absence of 
Dy, full-length Pink1 accumulates on the OMM and recruits cytosolic Parkin. In turn, 
Parkin initiates the downstream mitophagy process (Jin et al., 2010). 
 
In summary, Pink1 is directed to the outer mitochondrial membrane by a non-canonical 
import pathway. Partial insertion into the inner mitochondrial membrane and processing of 
the protein are at least to some extent dependent on the mitochondrial membrane potential.  
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Figure 2: Model of Pink1 import in the presence and absence of Δψ , respectively. In the presence of Δψ 
(left side), the presequence-like N-terminal segment of the Pink1 precursor (Pink1p64) drives the 
translocation of Pink1 across the OMM via the TOM complex and its insertion into the IMM via the TIM23 
complex (1a). The inner membrane stop-transfer signal prevents complete translocation of Pink1 over the 
IMM. The N-terminus of Pink1 reaches the matrix, allowing cleavage of the mitochondrial targeting signal 
by the matrix processing peptidase (MPP) (2). The IMM protease PARL cleaves Pink1p64 at position 104, 
generating the processed form Pink1f53, which is released from the import machinery (3). A fraction of 
Pink1f53 associates with the OMM as a peripheral membrane protein, possibly assisted by the very C-
terminal fraction of the polypeptide. Alternatively, Pink1f53 is degraded by the proteasome. In depolarized 
mitochondria (right side), the Pink1 precursor (Pink1p64) associates with the OMM, possibly via TOM 
components. Accumulating Pink1 recruits Parkin, which in turn induces mitophagy (1b). OMM, outer 
mitochondrial membrane; IMS, intramembrane space; IMM, inner mitochondrial membrane. Modified after 
(Becker et al., 2012a).  
 
1.5 Degradation of Pink1  
The electrochemical potential over the inner mitochondrial membrane is not only a 
requirement for import of mitochondrial preproteins into the matrix compartment but also 
indicative of active oxidative phosphorylation and mitochondrial integrity. Therefore, the 
loss of Δψ has traditionally been used as a measure for the degree of mitochondrial 
dysfunction. Vice versa, chemical uncoupling of Δψ e.g. by the ionophore valinomycin or 
the protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) is routinely 
utilized to simulate mitochondrial damage in cell culture models. While both full-length 
and processed Pink1 are virtually undetectable under normal conditions, the full-length 
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form accumulates upon depletion of Δψ by exposure of cells to CCCP (Jin et al., 2010, 
Narendra et al., 2010b, Zhou et al., 2008). Moreover, a relatively fast decrease in Pink1 
levels upon recovery of Δψ was reported. These observations led to the initial hypothesis 
that the low steady-state levels of Pink1 in healthy mitochondria result from constitutive 
and rapid degradation of the imported and processed form of Pink1 (Matsuda et al., 2010). 
By this mechanism, Pink1 was postulated to accumulate specifically on depolarized 
mitochondria to signal mitochondrial damage (Narendra et al., 2010b). Concerning the 
protease responsible for Pink1 degradation, several publications proposed an involvement 
of the proteasome, as proteasomal inhibitors stabilize the processed form of Pink (Lin & 
Kang, 2008, Takatori, Ito et al., 2008). Degradation of Pink1 was further demonstrated to 
follow the N-end rule, meaning that susceptibility of a protein to degradation via the 
ubiquitin-proteasome system is determined by its N-terminal amino acid (Yamano & 
Youle, 2013). By contrast, another study postulated degradation of Pink1 inside the matrix 
compartment, catalyzed by the mitochondrial protease Lon (Thomas, Andrews et al., 
2014). Notably, the latter observation is largely inconsistent with a localization of Pink1 at 
the outer mitochondrial membrane described above. 
 
Taken together, according to the current model, mitochondrial Pink1 amounts are 
regulated through Δψ−dependent import and degradation of the protein. By this 
mechanism, Pink1 is postulated to accumulate on depolarized mitochondria to act as a 
sensor of mitochondrial damage. Notably, this hypothesis is based on the inner membrane 
potential as the sole measure for mitochondrial damage. However, it is not clear how the 
complete depolarization of virtually all mitochondria within a cell, experimentally caused 
by CCCP translates to physiological and pathophysiological conditions. Thus, the 
authentic cause for the fast increase in Pink1 levels in response to mitochondrial 
perturbations is not yet clear. In addition, the proposed import/turnover model raises the 
question if the 53 kDa major cleavage product of Pink1 represents merely a degradation 
intermediate or if it fulfills any specific function. 
 
1.6 Pink1/Parkin-mediated mitophagy 
After Pink1 accumulates on depolarized mitochondria, it recruits the usually cytosolic 
E3 ubiquitin-protein ligase Parkin. In turn, Parkin initiates a downstream pathway that 
eventually leads to mitophagy, a mitochondria-specific type of macroautophagy. In brief, 
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autophagy describes the sequestration of a portion of the cytoplasm, protein aggregates or 
whole organelles in a double membrane structure, termed autophagosome. The 
autophagosome then fuses with a lysosome, delivering its content to degradation by 
lysosomal enzymes (Figure 3). While non-specific autophagy of intracellular components 
occurs in response to nutrient starvation, autophagy can be highly selective for specific 
organelles, including mitochondria (Wang & Klionsky, 2011). Mitophagy mediates the 
removal of mitochondria during erythrocyte development (i), eliminates paternal 
mitochondria in fertilized oocytes (ii) and is responsible for the clearance of irrevocably 
damaged mitochondria (iii). While all three mitophagy pathways are thought to utilize 
core components of the autophagic machinery, the preceding events that lead to the 
initiation of mitophagy are likely distinct. In response to mitochondrial damage, Pink1 and 
Parkin function together to mediate mitophagy (Ashrafi & Schwarz, 2013). 
 
Using Drosophila knockout models, loss of Pink1 or Parkin, respectively, was 
demonstrated to result in similar mitochondrial defects, namely muscle degeneration, cell 
death and mitochondrial abnormalities. Complementation analysis further revealed that 
Pink1 functions upstream of Parkin in a common pathway (Clark, Dodson et al., 2006, 
Park, Lee et al., 2006). In human cells exposed to CCCP, Parkin was subsequently shown 
to translocate from the cytosol to mitochondria upon loss of Δψ. Moreover, Parkin was 
proposed to mediate the autophagic removal of damaged mitochondria (Narendra, Tanaka 
et al., 2008). Providing an explanation for their genetic interaction, Pink1 was finally 
demonstrated to be responsible for Parkin translocation to depolarized mitochondria 
(Geisler, Holmstrom et al., 2010b, Matsuda et al., 2010, Narendra et al., 2010b, Vives-
Bauza, Zhou et al., 2010, Ziviani, Tao et al., 2010). In addition, the usually repressed 
ubiquitin ligase function of Parkin was activated upon its Pink1-mediated translocation to 
mitochondria (Narendra et al., 2010b). 
 
Pink1-dependent recruitment of Parkin to mitochondria and subsequent induction of 
mitophagy require the kinase function of Pink1 (Geisler et al., 2010b, Matsuda et al., 
2010, Narendra et al., 2010b). This notion raised questions concerning Pink1 
phosphorylation targets and a putative mechanism of Pink1-mediated mitochondrial 
translocation and activation of Parkin. As an E3 ubiquitin ligase, Parkin catalyzes the 
transfer of the of the 76 aa protein ubiquitin (Ub) from an E2 ubiquitin-conjugating 
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enzyme to the ε- amino group of a substrate protein’s lysine residue. The acceptor protein 
can be another ubiquitin, in which case polyubiquitin chains are formed (Ciechanover, 
2005). Depending on the length and linkage type of Ub modifications, substrate proteins 
are tagged for signaling processes or degradation, by the proteasome, the lysosome or 
autophagy (Clague & Urbe, 2010). Parkin is capable of catalyzing monoubiquitination, as 
well as the addition of different types of polyubiquitin chains, including Lys48- and 
Lys63-linked chains to its substrate proteins (Hampe, Ardila-Osorio et al., 2006, Seirafi, 
Kozlov et al., 2015). Parkin consists of an N-terminal ubiquitin-like (Ubl) domain, linked 
to four zink-finger domains, three of which form a RING1-In-Between-RING2 (RBR) 
motif (Figure 37, appendix). Accordingly, it is classified as an RBR-type E3 enzyme 
(Trempe & Fon, 2013). Using in vitro and in vivo techniques, Pink1 was demonstrated to 
directly phosphorylate Parkin at Ser65 within the UBL domain (Kondapalli, Kazlauskaite 
et al., 2012). This phosphorylation was initially proposed to relieve an autoinhibitory 
mechanism of Parkin, thereby promoting its enzymatic activity (Kondapalli et al., 2012, 
Shiba-Fukushima, Imai et al., 2012). Intriguingly, Parkin carrying a Ser65Ala mutation to 
abolish its phosphorylation, as well as a Parkin mutant lacking the Ubl domain, still 
translocate to mitochondria in a Pink1-kinase dependent manner (Kane, Lazarou et al., 
2014). An explanation for this observation lies within a recently discovered novel 
mechanism, in which Pink phosphorylates ubiquitin at Ser65 (homologous to Ser65 in the 
Parkin Ubl domain) and in turn, phospho-ubiquitin activates the Parkin E3 ligase activity 
(Kane et al., 2014, Kazlauskaite, Kondapalli et al., 2014, Koyano, Okatsu et al., 2014). 
According to a recently proposed feed-forward model, Pink1-mediated phosphorylation 
activates Parkin, which in turn, ubiquitinates proteins on the mitochondrial surface. Pink1 
then phosphorylates these newly formed polyubiquitin chains, generating phospho-
ubiquitin, which further promotes Parkin activity (Ordureau, Sarraf et al., 2014). 
 
Once activated, Parkin ubiquitinates proteins at the outer face of the outer mitochondrial 
membrane (Geisler, Holmstrom et al., 2010a, Narendra, Kane et al., 2010a, Sarraf, Raman 
et al., 2013). Notably, the broad spectrum of Parkin OMM substrates identified in a 
proteomics approach by Sarraf et al. suggests that the overall ubiquitination pattern, rather 
than a specific substrate is crucial for the subsequent signaling process (Sarraf et al., 
2013). The current model of Pink1/Parkin-mediated mitophagy is illustrated in Figure 3. 
Although the events downstream of Parkin activity still have to be worked out in detail, it 
is proposed that cellular autophagic components recognize the ubiquitin chains attached to 
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OMM proteins and eventually mediate the mitophagy process (Ashrafi & Schwarz, 2013, 
de Vries & Przedborski, 2012, Geisler et al., 2010a, Pickrell & Youle, 2015). In general, 
mitophagy utilizes the core autophagy machinery, comprising numerous so-called 
autophagy-related (Atg) proteins, which were initially identified in yeast. Among them is 
LC3, one of several human Atg8 homologs, which is conjugated to 
phosphatidylethanolamine residues of the forming autophagic membrane. Adaptor 
proteins that interact with both mitochondrial and autophagic proteins, including LC3, 
mediate organelle specificity of the mitophagy process (Wang & Klionsky, 2011). In case 
of Pink1/Parkin-dependent mitophagy, the autophagy adaptor p62 may be recruited to 
ubiquitinated mitochondria albeit its requirement for the mitophagy process as such 
remains controversial (de Vries & Przedborski, 2012, Geisler et al., 2010a, Narendra et al., 
2010a). Other candidate adaptor proteins are the Bcl-2 family member Nix, NBR1, 
Tax1BP1, NDP52, and optineurin (de Vries & Przedborski, 2012, Pickrell & Youle, 
2015). In case of NDP52 and optineurin, a recent study elucidated their direct recruitment 
by Pink1 to phospho-ubiquitin. Remarkably, Parkin was dispensable for this process, 
which emphasizes a more direct function of Pink1 in the mitophagy process (Lazarou, 
Sliter et al., 2015). Notably, most of the work characterizing the Pink1/Parkin system has 
been carried out in immortalized cell lines and frequently utilizing overexpression of at 
least on of the two proteins. Hence the question to what extent endogenous Pink1 and 
Parkin contribute to mitophagy in neurons remains to be answered (Grenier, McLelland et 
al., 2013). 
 
It should be noted that recruitment of Parkin and the autophagic machinery is likely only 
one of several functions of Pink1 in a broader context of mitochondrial quality control. 
Within the cell, mitochondria do not exist as isolated organelles but constitute a dynamic 
network, which is constantly recomposed by fusion and fission (Youle & van der Bliek, 
2012). Fusion of the outer membrane is mediated by the GTPases Mitofusin 1 and 
Mitofusin 2 (Mfn1 and Mfn2). Both proteins are ubiquitinated in a Pink1/Parkin-
dependent manner to be degraded by the proteasome (Gegg, Cooper et al., 2010, Tanaka, 
Cleland et al., 2010) and at least Mfn2 is also a direct Pink1 substrate (Chen & Dorn, 
2013). Abolishing fusion through degradation of Mfn1/Mfn2 prevents severely damaged 
mitochondria from refusing with and poisoning the mitochondrial network (Youle & van 
der Bliek, 2012). Moreover, the resulting smaller mitochondria are thought to be better 
accessible targets for the mitophagy process (de Vries & Przedborski, 2012). Transport of 
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mitochondria along microtubules confers mitochondrial motility, as exemplified by axonal 
transport. The mitochondrial Rho GTPase Miro1 acts as an adaptor between mitochondria 
and kinesin motor proteins. Upon loss of Δψ, Pink1, together with Parkin, activates the 
proteasomal degradation of Miro1, which results in a halt of mitochondrial motility. The 
resulting spatial isolation may facilitate removal of the damaged organelle by mitophagy 
(Wang, Winter et al., 2011).  
 
Finally, the mitochondrial Hsp90 chaperone TRAP1 and the IMM protease HtrA2 (see 
1.2) were demonstrated to be phosphorylated by Pink1 (Plun-Favreau, Klupsch et al., 
2007, Pridgeon, Olzmann et al., 2007). A spatial interaction of the cytosol-exposed Pink1 
kinase domain with the matrix resident TRAP1 is unlikely. However, TRAP1 
overexpression completely rescues the Pink1-deficient phenotype in flies, pointing 
towards a certain functional redundancy of Pink1 and TRAP1 (Costa, Loh et al., 2013). 
Similarly, regulation of HtrA2, a candidate constituent of PQC may implicate a function 
of Pink1 in mitochondrial homeostasis beyond mitophagy.  
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Figure 3: Current model of Pink1/Parkin-mediated mitophagy. Under normal conditions, Pink1 levels 
are very low. Mitochondrial stress conditions may lead to mitochondrial damage, accompanied by a decrease 
or loss of the mitochondrial membrane potential (Δψ) (1). In the absence of Δψ, Pink1 accumulates at the 
outer mitochondrial membrane (OMM) (2). Pink1 recruits and activates the usually cytosolic E3 ubiquitin 
ligase Parkin in a process involving Pink1-mediated phosphorylation of Parkin at Ser65 (3). Parkin 
conjugates ubiquitin (Ub) to various OMM proteins (4). Pink1 phosphorylates Ub attached to OMM 
proteins, and the resulting phospho-Ub further activates Parkin (5). Adaptor proteins (candidate proteins are 
indicated) that bind to both ubiquitin and the autophagic protein LC3 mediate sequestration of the organelle 
in an autphagosomal membrane (6). The autophagosome then fuses with a lysosome, delivering its complete 
content to degradation by lysosomal hydrolases (7). 
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2 Objectives of this work 
The mechanisms, whereby the PD-related mitochondrial kinase Pink1 initiates the 
autophagic removal of defective mitochondria via the recruitment and activation of Parkin, 
have been extensively studied. By contrast, the preceding events, leading to a significant 
increase in the amount of Pink1 polypeptides at the outer mitochondrial membrane of 
impaired mitochondria are by far less understood. The current model states that Pink1 
amounts are regulated via membrane potential-dependent import and concomitant fast 
turnover of the protein. The considerations leading up to this thesis were 1) that the 
proposed model presumes complete depolarization of virtually all mitochondria for the 
activation of the Pink1/Parkin system, a condition that seems unlikely to occur under 
physiological conditions and 2) that the constitutive synthesis and degradation of Pink1 
would consume an enormous amount of cellular energy. Thus, in my thesis I aimed at 
identifying conditions that elicit an increase in Pink1 protein levels. The main 
experimental strategy was to treat cultured human cells with diverse chemicals that 
modulate mitochondrial or cellular functions and monitor Pink1 protein levels under the 
respective conditions. Analyzing the functional state of mitochondria upon perturbations 
that elicit Pink1 accumulation would then possibly allow identifying a common trigger for 
Pink1 accumulation and concomitant mitophagy. In a second approach, the biochemical 
mechanism underlying the regulation of Pink1 protein amounts should be revisited. To 
this end, cellular and mitochondrial degradation assays were employed to directly assess 
the turnover of Pink1 both under normal conditions and mitochondrial perturbations that 
lead to elevated Pink1 levels. A third approach aimed at establishing a model for 
mitochondrial perturbations with a direct relevance for PD. The PD-related cytosolic 
protein α-synuclein, which has been proposed to exert harmful effects on mitochondria, 
represents a prominent candidate for such a model. As a prerequisite for future 
experiments, the putative interaction of α-synuclein with mitochondria should be analyzed 
by means of a radioactive in vitro import assay.  
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3 Materials  
3.1 Laboratory devices 
Device Name Manufacturer 
CCD camera LAS-400 mini Fujifilm 
Cell counter Scepter Milipore 
Flow cytometer CyFlow space CY-S3001 Partec 
Fluorescence microscope EVOS fl PeqLab 
Homogenizer Minilys PeqLab 
Microplate reader Infinite M200 pro TECAN 
Phosphorimager FLA-5100 Fujifilm 
Ultracentrifuge Optima Max-XP Beckman Coulter 
 
3.2 Chemicals  
Compound Supplier 
1-Methyl-4-phenylpyridinium iodide 
(MPP+) 
Sigma-Aldrich 
Actinomycin D Sigma-Aldrich 
Antimycin A Sigma-Aldrich 
Apyrase Sigma-Aldrich 
Atractyloside Calbiochem 
Carbonyl cyanide 3-
chlorophenylhydrazone (CCP) 
Sigma-Aldrich 
Creatine Roche 
Creatine Kinase Roche 
Cycloheximide Sigma-Aldrich 
Digitonin Calbiochem 
Dodecyl- β -D-maltosid Carl Roth 
Menadione Sigma-Aldrich 
1-Methyl-4-phenylpyridinium iodide 
(MPP+ iodide) 
Sigma-Aldrich 
MG132 (Z-leu-leu-leu-al) Sigma-Aldrich 
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Oligomycin Sigma Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) Carl Roth 
Proteinase K Sigma-Aldrich 
Protease inhibitor cocktail plus Carl Roth 
Rotenone Sigma-Aldrich 
Tetramethylrhodamine ethyl ester (TMRE) Life technologies 
 
3.3 Reagents 
Name Supplier 
ATP determination kit Life technologies 
EXPRESS [35S] protein labeling mix Perkin Elmer 
iScript Select cDNA synthesis kit BioRad 
Lipofectamine Life technologies 
MitoSOX mitochondrial superoxide 
detector 
Life technologies 
MitotrackerRed Life technologies 
mMESSAGE mMACHINE SP6 
Transcription kit 
Life technologies 
Molecular Weight Marker, low range Sigma Aldrich 
NativeMark protein standard Life technologies 
NucBlue® Live ReadyProbes™ Reagent Life technologies 
Plasmid DNA isolation kit Life technologies 
Rabbit Reticulocyte Lysate System Promega 
RNeasy Mini Kit Qiagen 
RotiQuant universal Carl Roth 
ServaLight EoSUltra CL HRP WB 
Substrate Kit 
Serva 
TNT-coupled reticulocyte lysate Promega 
TRIzol Life technologies 
TurboFect transfection reagent Theromo Scientific 
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3.4 Cell culture media and reagents 
Name Supplier 
Dulbeco’s modified Eagel’s medium 
(DMEM), high glucose 
Life technologies 
RPMI medium Life technologies 
Fetal calf serum (FCS) Life technologies 
Penicillin/Streptomycin Life technologies 
L-glutamine  Life technologies 
0.005 % Trypsin-EDTA Life technologies 
10 x PBS Life technologies 
 
3.5 Primary antibodies 
Immunogen Type Specification Source 
BiP/GRP78 mouse 610978 BD Biosciences  
COX1 mouse 459600 Invitrogen  
COX4 mouse 3E11 Cell Signaling  
COX5a mouse A21363 Molecular Probes  
DJ1 mouse - gift from S. Przedborski 
GAPDH mouse E1C603-1 EnoGene  
GRP75/Mortalin mouse SPS-825 Stressgen   
Hsp60 rabbit sc-13966 Santa Cruz Biotechnology  
Lon rabbit  Gramsch 
Mfn2 mouse  Abcam 
Parkin rabbit 2132 Cell Signaling  
Pink1 rabbit BC100-494 Novus Biologicals  
PMPCA (MPP) rabbit HPA021648 Sigma-Aldrich  
SDHA mouse 459200 Invitrogen  
Smac rabbit sc-22766 Santa Cruz Biotechnology  
Tim23 mouse 611222 BD Biosciences  
Tom40 rabbit sc-11414 Santa Cruz Biotechnology  
TRAP1 rabbit GR2387 Gramsch 
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α -Tubulin mouse T5168 Sigma-Aldrich  
FLAG-tag mouse FLAG M2 
affinity gel 
A2220 
Sigma 
 
3.6 Peroxidase-coupled secondary antibodies for Western blot  
Immunogen Type Specification Source 
Rabbit IgG goat A6154 Sigma-Aldrich 
Mouse IgG goat A4416 Sigma-Aldrich 
 
3.7 Mammalian cell lines 
Name  Description  Source 
SH-SY5Y human neuroblastoma German Collection of 
Microorganisms and Cell Cultures 
(DSMZ), ACC-209  
HeLa human cervix carcinoma DSMZ, ACC-57 
MEF PARL -/- mouse embryonic fibroblast Serge Przedborski 
 
3.8 Plasmids 
Name Description Source 
pHSPINK1 vector: pCMV-SPORT6, insert: human 
Pink1, CMV promoter for mammalian 
expression 
Imagenes 
pHSMDH2 vector: pOTB7, insert: human Mdh2; T7 
promoter for in vitro transcription 
Invitrogen 
pPINK1-FLAG vector: pIRES-hrGFP-1, insert: human Pink1 
with C-terminal FLAG-tag, CMV promoter 
for mammalian expression 
Serge 
Przedborski 
pPINK1DN103 vector: pCMV, insert: human Pink1 with Serge 
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deletion of 103 N-terminal amino acids, CMV 
promoter for mammalian expression 
Przedborski 
pSNCA-A30P vector: pCMV, insert: human α-synuclein 
with A30P mutation and C-terminal HA-tag, 
CMV promoter for mammalian expression 
Serge 
Przedborski 
pSNCA-A53T pCMV vector, insert: human α-synuclein with 
A53T mutation and C-terminal HA-tag, CMV 
promoter for mammalian expression 
Serge 
Przedborski 
pSNCA-HA-WT vector: pCMV, insert: human α- synuclein 
with C-terminal HA tag, CMV promoter for 
mammalian expression 
Serge 
Przedborski 
pSU9-GFP vector: pcDNA3.1, insert: GFP fused to first 
70 amino acids of N.crassa ATPase subunit 9 
(Su9(70)),CMV promoter for mammalian 
expression 
Ursula Gerken 
pSU9-GFP-DHFR vector: pcDNA3.1, insert: mouse full length 
DHFR with N.crassa Su9(70) and GFP fused 
to N-terminus, CMV promoter for 
mammalian expression 
Nadja 
Schröder 
pSU9-GFP-DHFRds vector: pcDNA3.1, insert: destabilized mouse 
full length DHFR with N.crassa Su9(70) and 
GFP fused to N-terminus, CMV promoter for 
mammalian expression 
Nadja 
Schröder 
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Primers for qRT-PCR 
Name Sequence 
PINK1 fwd 5’-AACATCCTTGTGGAGCTGGACCCAGACG-3’ 
PINK1 rev 5’-CATCAGCCTTGCTGTAGTCAATCACTG-3’ 
GAPDH fwd 5’- TCAGACACCATGGGGAAGGTGAA-3’ 
GAPDH rev 5’- GAATCATATTGGAACATGTAAACCATG-3’ 
 
3.9 Primers for PCR  
Name Sequence 
SP6-Koz-SNCA- fw 5’- GAATTCATTTAGGTGACACTATAGAATACGC
CGCCACCATGGATGTATTCATGAAAGGAC-3’ 
SNCA-stop-rev 5’-TCATCATCATTAGGCTTCAGGTTCGTAGT-3’ 
 
3.10 siRNA 
Transcript specification Source 
Mortalin (HspA9) SR30004 amsbio 
control  amsbio 
 
  
4 Methods 
 
23 
4 Methods 
4.1 Protein biochemical methods 
4.1.1 Glycine SDS-PAGE 
Discontinuous glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was routinely utilized to separate proteins according to their molecular weight and 
under denaturing conditions.  
 
Large Gel Resolving gel (12.5 %) Stacking Gel 
Acrylamide / 
bisacrylamide (37.5:1) 
mix  
6.9 ml 0.83 ml 
1.875 M Tris pH 8.8 3.5 ml - 
0.8 M Tris pH 6.8 - 0.5 ml 
10 % [w/v] SDS 0.17 ml 50 µl 
ddH2O 6.3 ml 3.55 ml 
10 % [w/v] APS 100 µl 50 µl 
TEMED 10 µl 10 µl 
Total volume 17 ml 5 ml 
 
Samples were resolved in 1 x SDS-PAGE sample buffer (8 % SDS, 40 % glycerol, 
240 mM Tris-HCl, pH 6, 0.08 % Bromphenol blue, 20 % β-mercaptoethanol) and heated 
to 95 °C for 5 min. Electrophoresis was conducted in 1 x SDS-buffer (25 mM Tris, 
0.191 mM glycine) at 25 mA for 3 -4 h.  
 
4.1.2 Tricine SDS-PAGE 
Tricine SDS-PAGE was used for the separation of small proteins, specifically α-synuclein. 
A 16.5 % acrylamide separation gel was overlaid with a 10 % acrylamide spacer gel and a 
stacking gel. Samples were prepared as described for glycine SDS-PAGE and 
electrophoresis was conducted in a two buffer system consisting of anode buffer 
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(0.2 M Tris-HCl, pH 8.9) and cathode buffer (0.1 M Tris, pH 8.25, 0.1 M tricine and 
0.1 % SDS) at 25 mA for 12-14 h. 
 
Acrylamide stock (32:1)  200 ml final concentration  
acrylamide 96 g 49.5 % 
bis-acrylamide 3 g 3 % 
ddH2O to 200 ml  
 
3 x gel buffer 500 ml final concentration 
Tris-HCl, pH8.5 181.71 3 M 
SDS 1.5 g 0.3 % 
ddH2O to 500 ml  
 
 
Gel 16.5 % 10 % stacking (4ml) 
acrylamide 
(32:1) 
5 ml 1 ml 0.417 ml 
3 x gel buffer 5 ml 1.67 ml 1.25 ml 
glycerol 2 ml - - 
ddH2O 3 ml 2.33 ml 3.33 ml 
10  % APS 75 µl 17 µl 42 µl 
TEMED 7.5 µl 1.7 µl 4.2 µl 
total volume 15 ml 5 ml 5 ml 
 
4.1.3 Blue native PAGE of mitochondrial proteins and protein complexes 
Mitochondrial proteins and protein complexes were analyzed by Blue native 
polyacrylamide gel electrophoresis (BN-PAGE). A 5-16.5 % polyacrylamide gradient 
resolving gel was prepared as following, by help of a gradient mixer, and overlaid with a 
stacking gel.  
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3 x gel buffer 500 ml final concentration 
ε -amino n-caproic acid 13.12 g 200 mM 
Bis-Tris/HCl pH 7.0 15.7 g 150 mM 
ddH2O to 500 ml  
 
Gel 5 %  16.5 % stacking gel 
3 x gel buffer 3 ml 3 ml 2.5 ml 
acrylamide 
(32:1) 
0.91 ml 3.05 ml 0.6 ml 
glycerol - 1.8 ml - 
ddH2O 5.048 ml 1.117 ml 4.367 ml 
10  % APS 38 µl 30 µl 30 µl 
TEMED 3.8 µl 3 µl 3 µl 
total volume 9 ml 9 ml 7 ml 
 
50 µg mitochondria per sample were solubilized in lysis buffer (1 % digitonin, 
10 mM HEPES, pH 7.4, 2 mM EDTA, pH 8.0, 50 mM NaCl, 10 % glycerol, 1 mM 
PMSF). After a clarifying spin to remove non-solubilized material, 10 x loading dye 
(5 % Coomassie blue G-250, 500 mM ε-amino n-caproic acid, 100 mM Bis-Tris-HCl, 
pH 7.0) was added and samples applied to the gel. The chamber was filled with pre-chilled 
anode buffer (50 mM Bis-Tris, pH 7.0) and samples overlaid with cathode buffer with 
Coomassie (50 mM Tricine, pH 7.0, 15 mM Bis-Tris/HCl, pH 7.0, 0.2 % Coomassie blue 
G-250), which was replaced by cathode buffer w/o Coomassie after the running front had 
reached the separation gel. The gel temperature was maintained at 4 °C using a cold water 
pump and electrophoresis conducted at 70 V for 16 to 20 h. The gel was finally soaked in 
1 x SDS buffer for 5 min and subjected to Western blotting as described below. 
 
4.1.4 Western blot and immunodetection of specific proteins 
Proteins separated by acrylamide gel electrophoresis were transferred to a polyvinylidene 
fluoride (PVDF) membrane using semi-dry Western blot technique. PVDF membranes 
were activated in methanol and pre-soaked in transfer buffer (20 mM Tris, 150 mM 
glycin, 0.1 % SDS, 20 % methanol), placed on three layers of filter paper soaked in 
transfer buffer, followed by the gel and three more layers of filter paper. Transfer was 
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conducted 220 mA for 2 h. After staining in Coomassie solution (0.25 % Coomassie 
Brilliant Blue R250, 40 % methanol, 10 % acetic acid) and destaining in destaining 
solution (40 % methanol, 10 % acetic acid) for visualization of total proteins, the 
membrane was incubated in blocking solution (5 % milk, 0.5 % Tween 20 in TBS) for 1 h. 
After incubation with a specific primary antiserum diluted in TBS containing 0.5 % 
Tween 20 at 4 °C o/N, membranes were washed three times in TBS, followed by 
incubation with anti-mouse- or anti-rabbit IgG antibody coupled to horseradish peroxidase 
diluted 1:5000 for 1 h at RT, and washing three times in TBS. Western blot membranes 
were developed using enhanced chemiluminescence (ECL) substrates and a charge 
coupled device (CCD) camera. 
 
4.1.5 Quantification of Western blot signals 
Where indicated, Western blot signals were quantified by means of MultiGauge software 
(Fujufilm). 
 
4.1.6 TCA precipitation of proteins 
TCA precipitation was used to concentrate proteins from dilute samples. 1/5 of final 
volume of 72 % trichloroacetic acid (TCA) was added to samples and mixed. After 30-40 
min incubation on ice, samples were centrifuged at 20,000 g for 40 min at 4 °C. Pellets 
were washed with ice-cold acetone and centrifuged at 20,000 x g for 12 min. Pellets were 
air-dried for 2 min and finally resuspended in 1 x SDS-PAGE sample buffer. 
 
4.1.7 Determination of protein concentration by modified BCA assay 
Protein concentration was routinely determined by means of modified BCA (bicinchoninic 
assay) assay (RotiQuant universal, Carl Roth). 5 µl of each sample or of a BSA serial 
dilution were pipetted in a 96 well plate. A RotiQuant working solution containing 
15 parts of reagent 1 and 1 part of reagent 2 was prepared and 200 µl of the working 
solution added to each well. After 30 min incubation at 37 °C, the absorbance at 492 nm 
was read in a microplate reader.  
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4.1.8 Alkaline extraction of proteins  
For alkaline extraction of mitochondrial proteins, 50 µg of isolated mitochondria (see 
2.4.2) were resuspended in 500 µl of 0.1 M sodium carbonate (Na2CO3) / sodium 
bicarbonate (NaHCO3) solution at pH 7.3, 10, 11.5 or 12, respectively and briefly mixed 
by vortexing. After 30 min incubation on ice, samples were subjected to 
ultra-centrifugation at 100,000 x g for 1 h at 4 °C. Supernatants were TCA-precipitated 
and all samples analyzed by SDS-PAGE and Western blot. 
 
4.1.9 In vitro transcription and translation  
Radiolabeled precursor proteins for in vitro import were synthesized in cell-free 
transcription and translation systems. For uncoupled transcription and translation, mRNA 
was produced from linearized plasmid DNA using the SP6-transcription kit (Promega). 
The obtained mRNA was used as a template for in vitro translation in the presence of 
[35S]-methionine/cysteine by means of reticulocyte lysate system (Promega). For 
transcription of SNCA constructs, transcription template DNA was amplified from the 
HA-tagged plasmids by standard PCR reaction, introducing SP6 promoter and Kozak 
sequence via the 5’-primer followed by uncoupled transcription and translation reactions 
as described. Coupled transcription/translation was conducted using the TNT-coupled 
reticulocyte lysate system (Promega) and linearized plasmid DNA as a template.  
 
4.2 Cell culture methods  
4.2.1 Cell culture conditions 
Cell line Culture medium 
SH-SY5Y DMEM, 10 % FCS, 1 mM L-glutamine, 100 units/ml penicillin, 
100 µg/ml streptomycin 
HeLa RPMI, 10 % FCS, 2 mM L-glutamine, 100 units/ml penicillin, 
100 µg/ml streptomycin 
MEF DMEM, 10 % FCS, 2 mM L-glutamine, 100 units/ml penicillin, 
100 µg/ml streptomycin 
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All cell lines were maintained in 10 cm or 15 cm diameter tissue culture dishes at 37 °C in 
a saturated humidity atmosphere containing 5 % CO2. Cells were passaged by 
trypsinization at ratios of 1:3 to 1:6 every 48 to 72 h and routinely tested for Mycoplasma 
contamination by PCR. 
 
4.2.2 Chemical treatment of cells 
SH-SY5Y cells were grown to 70-80 % confluency and then incubated in complete 
DMEM medium supplemented with the respective compound or corresponding amounts 
of EtOH/DMSO for control samples. Concentrations and incubation times were as 
specified in the figure legends. 
 
4.2.3 Transient transfection of cultured cells 
For transfection with plasmid DNA, cells were grown to a confluency of 70 to 90 % and 
transfected by means of TurboFect™ transfection reagent (Thermo Scientific) according 
to the manufacturer’s instructions and used for experiments 24 to 72 h post-transfection. 
 
4.2.4 Knock-down of protein expression by siRNA 
For knock-down of protein expression, cells were grown in 6-well plates to a confluency 
of 50 to 70 % in growth medium w/o antibiotics and transfected with siRNA by means of 
Lipofectamine™ reagent according to the manufacturer’s instructions using 100-pmol of 
siRNA and 5 µl transfection reagent per well. Cells were used for experiments 24 to 72 h 
post-transfection. 
 
4.3 Cell biology methods 
4.3.1 Lysis of cultured cells 
Cells were harvested using a cell scraper, washed twice in PBS and resuspended in lysis 
buffer (0.5 % Triton X-100, 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 50 mM NaCl, 
0.5 mM PMSF, 1 x protease inhibitors). Incubation at 4 °C with shaking at 1400 x rpm 
was followed by a clarifying spin at 1200 x g for 5 min to remove unlysed cells. The 
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protein concentration of the cleared lysate was determined (see 4.1.7) and 20 mg protein 
per lane were loaded for SDS-PAGE. 
 
4.3.2 Subcellular fractionation of cultured cells 
After harvesting, cells were washed twice in ice-cold PBS and resuspended in HMS-A 
buffer (220 mM mannitol, 70 mM sucrose, 20 mM HEPES, pH 7.6, 1 mM EDTA, 
0.2 % BSA, 1 mM PMSF). Cells were homogenized using a glass/Teflon homogenizer 
and cell lysates subjected to a clarifying spin at 1500 x g for 5 min. The supernatant was 
separated into mitochondrial and cytosolic fraction at 12,000 x g. The resulting 
mitochondrial pellet was washed once in HMS-B buffer (220 mM mannitol, 70 mM 
sucrose, 20 mM HEPES, pH 7.6, 1 mM EDTA, 1 mM PMSF) and finally resuspended in 
HMS-B. When analyzed in the respective experiment, cytosolic fraction were TCA-
precipitated.  
 
4.3.3 Preparation of mitochondrial fractions from muscle biopsies 
To obtain mitochondria-enriched fractions from human muscle biopsies, 25-100 mg of 
muscle tissue was homogenized in 20 µl ice-cold HMS-B buffer per mg tissue by means 
of a Minilys® homogenizer using 1.4 mm ceramic beads. After pelleting of cell debris at 
600 x g for 80 s, the supernatant was re-centrifuged at 17,000 x g for 5 min. The resulting 
mitochondrial pellet was washed twice in HMS-B. For subsequent analysis by Blue native 
PAGE, mitochondrial fractions were resuspended in DDM lysis buffer (0.02 M Tris-HCl, 
pH 7.4, 2 mM EDTA, 0.05 M NaCl, 10 % glycerol, 1 mM PMSF, 2.5 mg/ml n-dodecyl b-
D-maltoside) to a final concentration of 1 µg protein / µl. Experiments with patient 
samples were carried out under supervision of Prof. Dr. W. Kunz (Department of 
Epileptology and Life and Brain Center, University of Bonn) and according to the 
guidelines of the Ethical committee of the University of Bonn Medical Center.  
 
4.3.4 In vitro import of [35S]-labeled precursor proteins into isolated 
mitochondria 
For in vitro import of [35S]-Met/Cys-labeled precursor proteins, 50 µg of freshly isolated 
mitochondria were resuspended in 100 µl import buffer (20 mM HEPES, pH 7.6, 0.25 M 
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sucrose, 5 mM magnesium acetate, 80 mM potassium acetate), supplemented with 5 mM 
glutamate, 5 mM malate, 1 mM DTT, 5 mM KPi, pH 7.4 and 2 mM ATP. Where 
indicated, the mitochondrial membrane potential (Δψ) was dissipated by the addition of 
8 µM antimycin A, 0.5 µM valinomycin, and 20 µM oligomycin prior to import. 
Following the addition of radiolabeled precursor proteins, reactions were incubated at 
37 °C for the indicated times. Mock samples contained radiolabeled pre-proteins diluted in 
import buffer but no mitochondria. Mtochondria were re-isolated at 12,000 x g, washed 
once in import buffer and samples analyzed by SDS-PAGE and digital autoradiography. 
Where indicated, mitochondria were incubated in the presence of 100 µg/ml trypsin for 
30 min on ice after import to digest protease-accessible proteins (post-treatment). In order 
to access dependency of the import reaction on protease-accessible components of the 
TOM translocation complex, mitochondria were treated with trypsin or proteinase K at 
concentrations indicated in the respective figures for 25 min on ice prior to import (pre-
treatment).  
 
4.3.5 Mitochondrial re-translocation assay 
For the mitochondrial re-translocation assay, import of [35S]-labeled precursor proteins 
was performed as described for 30 min at 30 °C. After completion of the import reaction, 
mitochondria were re-isolated at 12,000 x g for 10 min and resuspended in 30 µl import 
buffer supplemented with 5 mM malate, 5 mM glutamate and 2 mM ATP. Where 
indicated Δψ  was dissipated by addition of a mixture of 8 µM antimycin A, 
0.5 µM valinomycin and 20 µM oligomycin and mitochondria resuspended in import 
buffer w/o supplements. Samples were incubated at 30 °C for the indicated times and then 
separated into mitochondrial pellet and soluble fraction at 12,000 x g for 10 min. The 
soluble fraction was TCA- precipitated and all samples finally resuspended in SDS-PAGE 
sample buffer. After separation by SDS-PAGE, samples were analyzed by digital 
autoradiograohy. 
 
4.3.6 Mitochondrial degradation assay 
To follow the degradation of newly imported radiolabeled proteins by mitochondrial 
proteases, in vitro import was conducted as described for 40 min. After completion of the 
import reaction, mitochondria were re-isolated, washed once in import buffer to remove 
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unbound preproteins and resuspended in 30 µl fresh import buffer, supplemented with 
1 mM creatine phosphate, 75 µg/ml creatine kinase and 7.5 µg/ml BSA. Where indicated, 
mitochondria were depleted of Δψ by addition of 8 µM antimycin A, 0.5 µM valinomycin 
and 20 µM oligomycin. For degradation in the absence of ATP, mitochondria were pre-
incubated with 0.01 U/µl apyrase and 20 µM oligomycin for 10 min at 30 °C and then 
incubated in import buffer w/o glutamate, malate and ATP-regenerating system but 
supplemented with 10 mM EDTA. Degradation reactions were incubated at 30 °C and 
after different time points, samples were withdrawn and mixed directly with SDS-PAGE 
sample buffer. All samples were analyzed by SDS-PAGE and digital autoradiography. 
 
4.3.7 Cellular degradation assay 
To monitor cellular degradation of Pink1 under different conditions, SH-SY5Y cells 
transiently expressing Pink1-FLAG, were subjected to radioactive cellular pulse/chase 
labeling, followed by immunoprecipitation specifically of Pink1-FLAG using an anti-
FLAG antibody.  
 
4.3.7.1 Cellular pulse/chase labeling 
24 h post-transfection with pPINK1-FLAG, cells were incubated for 1 h in depletion 
medium (Met/Cys free DMEM supplemented with 10 % FCS dialyzed against PBS and 
1 mM L-glutamine) under normal culture conditions to deplete intracellular methionine 
and cysteine. For pulse labeling, cells were incubated in depletion medium containing 
[35S]-Met/Cys-labeling mix with a specific activity of 22 mCi/ml in the medium for 
30 min. After washing once with complete DMEM, cells were further incubated in 
depletion medium supplemented with 30 mg/L cold methionine and 25 mg/L cold 
cysteine. After different chase incubation times, cells were scarped off from culture dished 
in PBS and whole cell suspensions subjected to TCA precipitation before proceeding with 
immunoprecipitation. 
 
4.3.7.2 Immunoprecipitation of Pink1-FLAG 
For immunoprecipitation, TCA precipitated proteins were lysed by boiling samples in 
denaturing lysis buffer (1 % SDS, 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 8 M urea). 
Lysates were diluted 1:10 in IP buffer (1 % Triton X-100, 50 mM Tris-HCl, pH 7.4, 
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150 mM NaCl, 50 mM EDTA, 1 mM PMSF, 1 x protease inhibitors) and subjected to a 
clarifying spin at 14,000 x g for 10 min. After determination of the protein concentration 
by BCA assay, equal amounts of protein were mixed with 25 µl of anti-FLAG antibody 
coupled to agarose beads (Anti-FLAG M2 affinity gel, Sigma A220) equibrilated in 
IP-buffer and incubated on a tube rotator at 4 °C o/N. Samples were washed three times in 
wash buffer (0.1 % Triton X-100, 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 5 mM EDTA, 
1 mM PMSF) before adding 40 µl SDS-PAGE sample buffer, shaking for 10 min, and 
boiling the samples at 95 °C for 5 min to elute bound proteins. Samples were analyzed by 
SDS-PAGE and digital autoradiography.  
 
4.3.8 Measurement of mitochondrial membrane potential (Δψ) in 
cultured cells by TMRE staining and flow cytometry  
The potential-sensitive fluorescent dye tetramethylrhodamine ethyl ester (TMRE) was 
used to assess Dy in intact SH-SY5Y cells. Following incubation in complete growth 
medium containing 0.5 µM TMRE for 20 min, cells were harvested by trypsinization and 
washed twice in PBS containing 0.2 % BSA. The red fluorescence of 20,000 cells per 
sample was analyzed by flow cytometry. Untreated cells and cells treated with the 
mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP) were 
analyzed as controls. 
 
4.3.9 Measurement of Δψ  in isolated mitochondria by TMRE staining 
and fluorescence intensity measurement 
For determination of Dy in isolated mitochondria, mitochondria were resuspended in 
potential buffer (0.6 M sorbitol, 0.1 % BSA, 10 mM MgCl2, 20 mM KPi, pH 7.2, 
5 mM malate, 10 mM glutamate) and incubated with 1 µM TMRE for 30 min at 30 °C and 
protected from light. Samples were washed once to remove excess TMRE and the TMRE 
fluorescence (excitation: 540 nm, emission: 585 nm) was measured in a microplate reader 
(Tecan Infinite M200 PRO, Tecan).  
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4.3.10 Measurement of oxygen radicals in cultured cells by MitoSOX 
staining and flow cytometry 
The superoxide indicator MitoSOX™ Red was utilized to detect superoxide radicals in 
living SH-SY5Y cells. Cells were treated with 10 µM menadione for 16 h and then 
incubated with Hank’s buffered salt solution (HBSS) containing 1 µM MitoSOX™ for 
10 min at 37 °C. After harvesting by trypsinization, cells were washed twice in HBSS 
containing 0.2 % BSA. The red fluorescence of 20,000 cells per sample was analyzed by 
flow cytometry. Untreated cells were analyzed as a control. 
 
4.3.11 Determination of cellular and mitochondrial ATP content 
The cellular and mitochondrial ATP content was measured by means of a luciferase based 
ATP assay. Cells were detached from culture plates by trypsinization, diluted to a final 
concentration of 1 x 106 cells/ml in PBS and permeabilized by incubation with 0.005 % 
digitonin for 5 min at 25 °C. Mitochondrial fractions were obtained by centrifugation of 
permeabilized cells at 12,000 x g for 5 min and washing once in PBS to remove cytosolic 
components. 0.5 x 104 cells or mitochondrial fractions of 1 x 106 cells per reaction were 
used for the ATP assay according to the manufacturer’s instructions and luminescence was 
measured in a microplate reader. An ATP standard curve was generated from reactions 
containing 0 to 160 picomoles ATP to confirm that the obtained values were in the linear 
range.  
 
4.3.12 Analysis of life cells by fluorescence microscopy 
For fluorescence microscopic analysis of living SH-SY5Y cells, transiently expressing 
SU9-GFP, SU9-GFP-DHFR or SU9-GFP-dsDHFR, 4 x 104 cells per well were seeded in 
24-well plates and transfected as described in 4.2.3. 48 h post-transfection, cells were 
incubated for 10 min in serum-free medium containing the mitochondria-specific dye 
MitoTracker Red at 250 nM and one drop per ml NucBlue Hoechst 33342 reagent for 
DNA specific staining of nuclei. After replacing the medium by PBS, cells were analyzed 
by fluorescence microscopy. 
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4.3.13 RT-PCR 
Cells were scraped off from culture dishes using a cell scraper and total RNA was isolated 
with the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, including 
an optional DNA digestion step. Random primed cDNA was produced by trancription of 
1 µg RNA of each sample using the iScript Select cDNA synthesis kit (Bio-Rad). mRNA 
expression of PINK1 was determined by quantitative Real-time PCR. PCR reactions were 
performed on an iQ5 qPCR system (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) 
under the following conditions: 95 °C for 5 min, and 45 cycles of 95 °C for 15 s and 
62.5 °C for 1 min. CT values were defined at the inflection points of fitted sigmoid curves 
(4-parameter Chapman curves) and were compared with those of the reference gene 
GAPDH (∆Ct-method). 
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5 Results 
5.1 Pink1 protein levels under mitochondrial stress conditions 
It is well established, that Pink1 accumulates at mitochondria upon uncoupling of the 
mitochondrial membrane potential (Δψ) upon exposure of cells to CCCP (Matsuda et al., 
2010). However, it was not clear if a complete dissipation of Δψ occurs under 
physiological conditions or during the etiology of PD. Thus, the question, if other 
mitochondria-specific stress conditions also lead to an accumulation of Pink1, was 
addressed in the following experiments.  
 
Note that all figures marked with an asterisk were prepared in collaboration with Nadja 
Schröder as part of an unpublished manuscript (Rüb, C., Schröder, N., Hallmann, K., 
Kunz, W. and Voos, W.: “Damage-related mitochondrial accumulation of Pink1 is based 
on a transcriptional induction reaction independent of the membrane potential”). 
 
5.1.1 Pink1 levels in response to inhibitors of oxidative phosphorylation 
The generation of ATP through oxidative phosphorylation is a key metabolic function of 
mitochondria. Accordingly, perturbation of this process should represent a state of severe 
mitochondrial dysfunction. Thus, SHSY-5Y cells were incubated with different inhibitors 
of respiratory chain complexes and the F1/F0-ATPase or CCCP as a control. Pink1 protein 
levels were then analyzed in total cell lysates by SDS-PAGE and Western blot (Figure 4). 
In accordance with previously reported results (Matsuda et al., 2010), the full-length form 
of Pink1 (Pink1-FL), with an apparent molecular weight of 64 kDa, was detected in 
CCCP-treated cells already after 8 h and further accumulated during 8 to 24 h of 
treatment. When cells were exposed to oligomycin, an inhibitor of the F1/Fo-ATPase, 
Pink1 also accumulated over time, although at a lower level compared to CCCP treatment. 
By comparison, Pink1 accumulation in cells treated with the complex III inhibitor 
antimycin A was similar to the CCCP control. Furthermore, high levels of Pink1 after 16 h 
of CCCP treatment and 24 h of oligomycin treatment, respectively, correlated with 
decreasing levels of the mitochondrial markers MPP and Tim23, while the amount of 
GAPDH as a cytosolic loading control remained unchanged under all conditions (Figure 4, 
lanes 3, 4 and 10). This decline in specifically mitochondrial proteins is consistent with 
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removal of mitochondria by Pink1-induced mitophagy. Notably, an accumulation of the 
53 kDa processed form of Pink1 (Pink1-PF) was not observed at any time point tested.  
 
 
Figure 4*: Effect of inhibitors of oxidative phosphorylation on cellular Pink1 protein levels. SH-SY5Y 
cells were incubated with DMSO/EtOH (control), 10 µM CCCP, 50 µM oligomycin (Oligo) or 200 M 
antimycin A (AA) for 8 to 24 h, respectively. Total cell lysates were analyzed by SDS-PAGE and Western 
blot using antibodies against Pink1, the mitochondrial processing peptidase (MPP), the TIM subunit Tim23 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as cytosolic control.  
 
To assess the effect of the OXPHOS inhibitors on mitochondria, measurements of the 
mitochondrial membrane potential (Δψ) and mitochondrial ATP levels were performed. 
First, to monitor Δψ, live cells were stained with the potential-sensitive fluorescent dye 
tetramethylrhodamine ethyl ester (TMRE) and analyzed by flow-cytometry (Figure 5). 
TMRE binds to the outer mitochondrial membrane (OMM) only in the presence of Δψ. In 
cells exposed to antimycin A, TMRE fluorescence was strongly reduced, indicating a 
dissipation of Δψ, almost identical to the CCCP control (Figure 5A). By contrast, the 
membrane potential of mitochondria in oligomycin-treated cells were even higher 
compared to untreated control cells (Figure 5B).  
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Figure 5*: Mitochondrial membrane potential measurements. After treatment with oligomycin or 
antimycin A for 16 h, mitochondrial membrane potential was determined in intact SH-SY5Y cells by TMRE 
staining and flow-cytometry. White: untreated, light grey: CCCP, dark grey: antimycin A (A) or oligomycin 
(B). Results are representative for at least three independent experiments per treatment. Note that for better 
visualization control plots for untreated and CCCP-treated cells are shown in both panels.  
 
Secondly, as a direct measure for oxidative phosphorylation, mitochondrial ATP content 
in cells exposed to the OXPHOS inhibitors was analyzed (Figure 6). To this end, 
mitochondrial fractions were obtained from digitonized cells and ATP levels determined 
by means of a luciferase-based ATP assay. As shown in Figure 6A, mitochondrial ATP 
levels in cells exposed to CCCP, oligomycin or antimycin A were strongly reduced to 
about 10 to 30 % of the untreated control. By contrast, cellular ATP levels were largely 
unchanged under the same conditions, confirming a mitochondria-specific effect of the 
cell treatment (Figure 6B). 
 
In order to determine, if the accumulation of Pink1 observed in Figure 3 occurred at 
mitochondria, cell homogenates from SH-SY5Y cells treated as above for 16 h, were 
separated into cytosolic and mitochondrial fractions (Figure 7). When Pink1 accumulated 
in response to CCCP, oligomycin and antimycin A, the protein completely co-fractionated 
with the mitochondrial markers MPP and Tom40 and was undetectable in the cytosolic 
fraction. As judged by GAPDH signals, a small amount of cytosolic proteins was present 
in the mitochondrial fraction. Accordingly, a minor fraction of the Pink1 signal in 
mitochondrial fractions may represent cytosolic Pink1, while the vast majority of Pink1 
was associated with mitochondria. 
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Figure 6*: Determination of mitochondrial (A) and cellular (B) ATP levels. After incubation with 
DMSO/EtOH, CCCP, oligomycin or antimycin A as described above for 16 h, a luciferase based ATP assay 
was performed. ATP amounts are given in percentage relative to untreated cells and represent the mean of 
three independent experiments for each condition tested. Error bars indicate the standard error of the mean 
(SEM).  
 
 
 
Figure 7: Subcellular localization of Pink1. After treatment of SH-SY5Y cells as described for Figure 3 
for 16 h, SH-SY5Y cell homogenates were separated into cytosolic (C) and mitochondrial (M) fraction by 
differential centrifugation and analyzed by SDS-PAGE and Western blot. Signals indicated with an asterisk 
most likely represent nonspecific signals from the Pink1 antibody. 
 
In Figure 4 Pink1 was already detectable at the earliest time point tested. Thus, the 
kinetics of Pink1 accumulation in response to CCCP and oligomycin was monitored more 
closely from 0.5 to 16 h of treatment (Figure 8). Pink1 started to become detectable after 
1 h of CCCP treatment or 4 h of exposure to oligomycin, respectively, and Pink1 protein 
levels strongly increased over the 16 h period tested. Interestingly, the decrease in MPP 
and Tim23 levels already observed in Figure 4 became evident only after 12 h of treatment 
5 Results 
 
39 
with CCCP or oligomycin. These results suggest, that either Pink1 levels need to reach a 
certain threshold to induce detectable mitophagy or that removal of mitochondria by 
mitophagy becomes detectable only after several hours upon induction.  
 
 
 
Figure 8: Time course of Pink1 accumulation after CCCP and oligomycin treatment. SH-SY5Y cells 
were incubated with CCCP or oligomycin as above for 0.5 to 16 h and Pink1 protein levels in total cell 
lysates analyzed by SDS-PAGE and Western blot. 
 
In summary, mitochondrial accumulation of Pink1 was observed under conditions that 
inhibit oxidative phosphorylation. This accumulation showed a rather slow kinetics and 
did not strictly correlate with the loss of Δψ. Mitochondrial localization of Pink1, together 
with a decline in mitochondrial proteins, which was dependent on high levels of Pink, 
corresponds to Pink1-mediated induction of mitophagy. 
 
5.1.2 Mfn2 ubiquitination 
Mitofusin2 (Mfn2) was previously reported to be ubiquitinated in a Pink1/Parkin- 
dependent manner upon CCCP-induced mitophagy and is also a direct phosphorylation 
substrate of Pink1 (Gegg et al., 2010). Hence, ubiquitinated Mfn2 may indicate Pink1 and 
Parkin activity. To analyze Mfn2 ubiquitination, Western blot analysis with 
immunodetection of Mfn2 was performed with total lysates of cells, exposed to the 
OXPHOS inhibitors as above (Figure 9). Under control conditions, the Mfn2-specific 
antibody recognized a single protein band. An additional band, at a slightly higher 
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apparent molecular weight, was detected in cell lysates of cells exposed to CCCP or 
antimycin A for 16 h. According to the molecular weight of a single ubiquitin molecule, 
monoubiquitination of Mfn2 would result in a size shift of 8.5 kDa. Thus, the additional 
band may correspond to monoubiquitinated Mfn 2. The additional Mfn2 signal was not 
detected in lysates from oligomycin-treated cells. Hence, the presence of the putatively 
ubiquitinated Mfn2 correlated with high levels of Pink1 as well as a decrease in 
mitochondrial proteins consistent with mitophagy. In conclusion, putative ubiquitination 
of Mfn2 may reflect the Pink1-dependent enzymatic activity of Parkin under conditions 
where Pink1 accumulates. 
 
 
5.1.3 Pink1 levels in response to inhibition of respiratory chain complex I 
When considering the respiratory chain in the context of Pink1 and Parkinson’s disease, 
complex I plays an exceptional role, as exposure to complex I inhibitiors has been shown 
to cause PD-like symptoms in humans and animal models Pickrell & Youle, 2015). Thus, 
the effect of complex I inhibition on Pink1 levels was investigated next. When SH-SY5Y 
cells were exposed to the complex I inhibitor rotenone at different concentrations for 
2 to 16 h, Pink1 did not accumulate at any time point tested (Figure 10A). As a control, 
mitochondrial and cellular ATP levels were determined as above. A reduction of 
mitochondrial ATP content by about 50 % relative to untreated cells (Figure 10B) and 
unchanged total ATP levels (Figure 10C) confirmed a mitochondria-specific effect of 
rotenone, under the experimental conditions tested here.  
Figure 9: Effect of Pink1 
accumulation on Mitofusin 2. 
SH-SY5Y cells were exposed to 
DMSO/EtOH (control), CCCP, 
oligomycin or antimycin A at 
concentrations as above for 8 h and 
total cell lystaes analyzed by 
SDS-PAGE and Western blot using an 
antibody against Mitofusin 2 (Mfn2). 
Signals indicated with an asterisk 
represent putatively 
mo-noubiquitinated Mfn2. 
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Figure 10: Effect of rotenone on cellular protein levels of Pink1, and ATP levels. Effect of rotenone on 
Pink1 levels. SH-SY5Y cells were treated with DMSO (control), CCCP or 0.5 or 1 µM rotenone (Rtn) for 
2 to 16 h. Pink1 levels in total cell lysates were analyzed by SDS-PAGE and Western blot. (B, C) 
Measurement of mitochondrial (B) or cellular (C) ATP levels. Cells were incubated in the presence 0.5 µM 
rotenone and ATP levels determined by luciferase assay as in Figure 6. 
 
Since the observation of unaltered Pink1 levels clearly distinguishes rotenone from the 
other inhibitors of OXPHOS (see Figure 4), cells were treated with an alternative 
complex I inhibitor. The drug 1-methyl-4-phenylpyridinium (MPP+) is the metabolite of 
the PD-related neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MTPT) (Singer, 
Ramsay et al., 1988).  
 
As seen in Figure 11A, Pink1 did not accumulate in response to MPP+ even after 24 h, 
while TMRE staining of cells treated with MPP+ for 24 h, indicated a strong reduction of 
the Dy  (Figure 11B). Hence, inhibition of complex I by MPP+ reflects a condition, where 
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a diminished Δψ does not result in the accumulation of Pink1. The failure of rotenone and 
MPP+ treatment to promote an accumulation of Pink1 raised the question, if inhibition of 
complex I interfered with the accumulation of Pink1 observed upon exposure of cells to 
the other OXPHOS inhibitors. Thus, SH-SY5Y cells were treated with CCCP or 
oligomycin as in Figure 4 but in the presence or absence of 0.5 µM rotenone for 8 and 
16 h, respectively. As shown in Figure 12, accumulation of Pink1 in response to CCCP, 
oligomycin and antimycin A was not affected by rotenone.  
 
 
 
Figure 11: Effect of MPP+ on Pink1 levels and Δψ . (A) Cells were treated with 2.5 mM 1-Methyl-4-
phenylpyridinium iodode (MPP+) for 8 to 24 h and Pink1 levels in whole cell lysates analyzed as above. (B) 
Mitochondrial membrane potential (Δψ) was determined in intact cells treated with DMSO (control), 10 µM 
CCCP or MPP+ for 24 h determined by TMRE staining and flow cytometry as in Figure 5. White: control, 
light grey: CCCP, dark grey: MPP+. 
 
Taken together, inhibition of complex I neither resulted in elevated protein levels of Pink1 
nor prevented accumulation of the protein in response to other stress conditions. 
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Figure 12: Effect of rotenone on Pink1 accumulation in response to CCCP and oligomycin. SH-SY5Y 
cells were treated with DMSO/EtOH (control), CCCP or oligomycin as above for 8 or 16 h in the presence 
or absence of 0.5 µM rotenone in serum-free medium. Total cell lysates were analyzed by SDS-PAGE and 
Western blot as above. 
 
5.1.4 Δψ-dependent protein complexes of Pink1 
Under native conditions, Pink1 has previously been found in two distinct membrane 
potential dependent protein complexes (Becker et al., 2012a). Presumably, these 
complexes comprise Pink1 and interacting proteins and may therefore harbor important 
information about functional consequences of Pink1 accumulation. A protein that is part 
of a complex with Pink1 should co-migrate with the respective Pink1 signal in Blue 
Native polyacrylamide gel electrophoresis (BN-PAGE). To revisit Pink1 complex 
formation, SH-SY5Y cells were incubated in the presence or absence of CCCP for 16 h. 
Mitochondria isolated from these cells were solubilized in digitonin buffer and analyzed 
by BN-PAGE and Western blot (Figure 13).  
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Figure 13: Δψ-dependent protein complexes of Pink1. SH-SY5Y cells were incubated with DMSO 
(control) or 10 µM CCCP for 16 h to dissipate Δψ, followed by isolation of mitochondria. Mitochondrial 
proteins and protein complexes were separated by BN-PAGE or standard SDS-PAGE as a control and 
analyzed by Western blot. 
 
In accordance with previously published results (Becker et al., 2012a), two complexes of 
about 700 and 900 kDa in mitochondria from CCCP-treated but not untreated control cells 
were detectable by a Pink1-specific antiserum (Figure 13, lanes 1 and 2). 
Immunodetection of Tom40 and Tim23, the core components of the TOM and TIM23 
translocase complexes, resulted in signals at about 450 and 240 kDa, corresponding to the 
fully assembled TOM and TIM complexes. However, no co-migration of the Tom40 or 
Tim23 signal with either Pink1 complex was observed. The anti-Tim23 antibody 
recognized an additional band, approximately in the range of the 900 kDa Pink1 complex 
but as opposed to the Pink1 signal, this band was strongly reduced in depolarized 
mitochondria. Thus, Pink1 did not form a complex with Tom40 or Tim23 under the tested 
experimental conditions. As Parkin is a phosphorylation substrate of Pink1 (Kondapalli et 
al., 2012, Shiba-Fukushima et al., 2012), it is a candidate for complex formation with 
Pink1. In mitochondrial fractions from control cells and CCCP-exposed cells, the 
anti-Parkin antibody recognized a complex at around 600 kDa, which did not co-migrate 
with either Pink1 complex (Figure 13, lanes 5 and 6). The proposed Pink1 substrate Mfn2 
(Chen & Dorn, 2013) was detected in two complexes of about 240 and 400 kDa, 
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respectively, in mitochondria from untreated control cells (Figure 13, lanes 7 and 8). No 
co-migration with either of the two Pink1 complexes was observed. Interestingly, in 
depolarized mitochondria, the amount of the 240 kDa complex was strongly reduced, 
similarly as observed for the TIM23 complex. The 400 kDa Mfn2 containing complex was 
undetectable in depolarized mitochondria. Since SDS-PAGE analysis revealed similar 
Mfn2 protein levels in both polarized and depolarized mitochondria, this decrease was not 
due to reduced protein amounts of Mfn2 but rather reflected a Δψ-dependent characteristic 
of the Mfn2 containing complexes.  
 
In summary Pink1 was found in two Δψ-dependent protein complexes of 700 and 900 kDa 
when it accumulated under mitochondrial stress conditions. These two Pink1 containing 
complexes did neither co-migrate with the fully-assembled TOM or TIM23 complex nor 
with the Pink1 substrates Parkin and Mfn2. 
 
5.2 Effect of protein stress conditions on Pink1 levels 
5.2.1 Overexpression of destabilized DHFR 
Challenging the protein quality control system reflects a mitochondrial stress condition 
that may elicit Pink1 accumulation and the downstream mitophagy process. Therefore, the 
effect of mitochondrial protein stress on Pink1 levels was investigated. In a first approach 
a mitochondrially targeted, destabilized form of the usually cytosolic protein dihydrofolate 
reductase (DHFR) was transiently expressed in HeLa or SH-SY5Y cells. The mutant 
protein comprises the full DHFR amino acid sequence with three point mutations that 
prevent folding of the protein (DHFRds), fused to GFP and an N-terminal mitochondrial 
translocation signal (SU9-GFP-DHFRds). The corresponding fusion construct of normal 
DHFR (SU9-GFP-DHFR) and mitochondrially targeted GFP (SU9-GFP) alone were used 
as controls. All three constructs are schematically shown in the appendix (Figure 36). 
 
In order to confirm mitochondrial localization of the fusion proteins and aggregation of 
the destabilized DHFR, HeLa cells were transiently transfected with the DHFRds construct 
or control constructs, respectively. Fluorescence microscopic analysis of live cells, stained 
with the fluorescent dyes Mitotracker Red and Hoechst for visualization of nuclei and 
mitochondria, 48 h post-transfection, is shown in Figure 14. In SU9-GFP-transfected cells, 
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GFP fluorescence showed perinuclear, filamentous structures, which co-localized with 
Mitotracker staining, indicating mitochondrial localization of the control protein. A very 
similar picture was obtained for cells expressing the SU9-GFP-DHFR protein. By 
contrast, in cells expressing SU9-GFP-DHFRds, GFP fluorescence was restricted to more 
condensed, dot like structures in proximity to the nucleus that predominantly co-localized 
with mitochondrial staining. This observation is consistent with aggregation of the 
destabilized DHFR protein inside mitochondria. 
 
 
Figure 14: Fluorescence microscopic analysis of cells expressing mitochondria-targeted destabilized 
DHFR or control constructs. HeLa cells were transiently transfected with the indicated construct. 48 h 
post-transfection, living cells were stained with MitoTracker Red and the DNA-specific dye Hoechst and 
analyzed by fluorescence microscopy. Scale bars indicate 100 µM. 
 
To test, if aggregation of the destabilized DHFR protein had an effect on Pink1 protein 
levels, SH-SH5Y cells were transfected with the different constructs for 24 to 48 h and 
total cell lysates were analyzed by SDS-PAGE and Western blot (Figure 15). Expression 
of all three fusion proteins was confirmed by immunodetection of GFP. The major signals 
at 30 kDa for SU9-GFP and 52 kDa for SU9-GFP-DHFR and SU9-GFP-DHFRds, 
respectively, correspond to the processed proteins, after cleavage of the mitochondrial 
targeting signal by the matrix processing peptidase (MPP). This observation indicates, that 
a major fraction of all proteins was translocated to the mitochondrial matrix. Additional 
bands, representing the full-length forms, were detected for SU9-GFP and 
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SU9-GFP-DHFR, respectively. The presence of the unprocessed fragments correlated with 
high expression levels, which likely exceeded the capacity of the import machinery. 
Compared to the DHFR construct, the DHFRds fusion protein was expressed at lower 
levels and its expression further declined over time, which was confirmed by 
immunodetection using a DHFR-specific antiserum. Since no apparent degradation 
fragments were detected with either the anti-GFP or the anti-DHFR antibody, 
comparatively low levels of the destabilized DHFR protein, were due to less efficient 
expression of the protein, rather than proteolytic degradation. Pink1 was not detectable, 
upon expression of DHFRds or the control constructs at any time point tested, as compared 
to Pink1 accumulation in SH-SY5Y cells treated with CCCP for 16 h  
 
In conclusion mitochondrially targeted destabilized DHFR as well as the two control 
proteins did localize to mitochondria. The SU9-GFP-DHFRds protein but not SU9-GFP-
DHFR or SU9-GFP aggregated inside mitochondria. Thus, SU9-GFP-DHFRds is a suitable 
model protein for mitochondrial protein aggregation in human cells. However, aggregation 
of destabilized DHFR did not elicit an accumulation of Pink1.  
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Figure 15: Pink1 levels in 
cells overexpressing 
mitochondria-targeted 
destabilized DHFR or 
control constructs. 
SH-SY5Y cells were 
transiently transfected with 
the indicated construct. Cells 
were lysed 24 to 72 h 
post-transfection and 
analyzed by SDS-PAGE and 
Western blot. Controls: Mock 
transfection containing no 
plasmid DNA and cells 
treated with 10 mM CCCP 
for 16 h.  
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5.2.2 Knock-down of Mortalin 
In a second approach, knock-down of the mitochondrial Hsp70 chaperone Mortalin 
(Grp75) was utilized to induce mitochondrial protein stress. Mortalin locates to the 
mitochondrial matrix, and is indispensible for protein import, folding of newly imported 
proteins and stress protection (Voos, 2013). Thus, SH-SY5Y cells were transiently 
transfected with Mortalin specific siRNA for 24 to 48 h or control siRNA and total cell 
lysates analyzed as above (Figure 16).  
 
 
Successful knock-down was evident by strongly reduced protein levels of Mortalin 
already after 24 h and a further decrease to about 15 % after 48 h, as compared to cells 
transfected with unspecific control siRNA (mock). Notably, cells analyzed 72 h 
post-transfection with control siRNA showed increased Mortalin levels as compared to 
cells exposed to DMSO or CCCP for 16 h. (Figure 16, lane 4). This effect may reflect a 
stress situation due to prolonged incubation of the cells. Protein levels of other members 
of the mitochondrial protein quality system were analyzed as a control. A correlation 
between diminished Mortalin levels and amounts of the mitochondrial chaperones Hsp60 
and TRAP1, the mitochondrial Hsp90 homologue, was not evident. By comparison, the 
level of the matrix protease Lon was slightly increased after 72 h of Mortalin knock-down, 
Figure 16: Effect of Mortalin 
knock-down on Pink1 levels. 
SH-SY5Y cells were transiently 
transfected with siRNA specific for 
the mitochondrial Hsp70 chaperone 
Mortalin (Grp75). 24 to 72 h 
post-transfection, total cell lysates 
were analyzed by SDS-PAGE and 
Western blot using antibodies against 
Pink1, Mortalin, the mitochondrial 
chaperones Hsp60 and TRAP1 
(mtHsp90) and the Lon protease. 
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compared to shorter time points. As compared to cells treated with CCCP for 16 h, Pink1 
did not accumulate in response to reduced levels of Mortalin. 
 
In conclusion, mitochondrial proteotoxic stress induced either by the ectopic expression of 
a destabilized mitochondria-targeted protein or knock-down of Mortalin did not result in 
an accumulation of Pink1. 
 
5.3 Effect of cellular stress conditions on Pink1 levels 
5.3.1 Oxidative stress 
Having observed an accumulation of Pink1 under specific mitochondrial stress conditions, 
the effect of general, cellular stress conditions on Pink1 levels was assessed next. 
Oxidative stress has previously been related to mitochondrial dysfunction and Parkinson’s 
disease (Lin & Beal, 2006). Thus, SH-SY5Y cells were treated with the 
superoxide-generating compound menadione for 16 h, and Pink1 protein levels in total 
cell extracts were analyzed as above. As seen in Figure 17A, menadione did not cause 
elevated levels of Pink1 at any concentration tested. To monitor the presence of 
superoxide radicals, cells exposed to 10 µM menadione for 16 h, were stained with the 
mitochondria-specific superoxide-sensitive fluorescent dye MitoSOX and analyzed by 
flow-cytometry (Figure 17B). A significantly higher MitoSOX fluorescence of 
menadione-treated cells compared to control cells clearly indicated an increase in 
superoxide radicals. 
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Figure 17*: Protein levels of Pink1 and superoxide radicals in menadione-treated cells.  
(A) SH-SY5Y cells were incubated with EtOH/DMSO or 10 µM CCCP (controls) or 2.5-5 µM menadione 
(Mnd) for 16 h and total cell lysates analyzed by SDS-PAGE and Western blot as above. (B) After treatment 
with EtOH (control) or 10 µM menadione for 16 h, superoxide radicals were detected in living SH-SY5Y 
cells by staining with the mitochondria-specific superoxide-reactive dye MitoSOX™ and flow cytometry. 
Grey: menadione, white: control. 
 
5.3.2 ER protein stress 
Within the cell, mitochondria and the endoplasmatic reticulum (ER) are functionally 
connected through processes like calcium homeostasis and lipid metabolism. Moreover, 
mitochondria and ER have been reported to share common structures, the so-called 
mitochondria-associated ER membranes (MAM) (Paillusson, Stoica et al., 2016). 
Accordingly, ER stress conditions might be propagated to mitochondria and cause an 
accumulation of Pink1. To test this hypothesis, SH-SY5Y cells were exposed to 
tunicamycin, a compound that causes unfolded protein stress in the ER by blocking 
N-linked glycosylation, which is required for the proper folding of specific proteins. As 
seen in Figure 18A, cellular Pink1 amounts were not increased after 16 h of incubation 
with tunicamycin at different concentrations. Under the same conditions, levels of the ER 
chaperone BiP (immunoglobulin heavy chain binding protein) were elevated even at 
1 µg/ml tunicamycin, indicating an ER-specific effect of the tunicamycin treatment 
(Figure 18B) Upregulation of BiP is part of the unfolded protein response (UPR) in the ER 
(Behnke, Feige et al., 2015). 
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5.3.3 Inhibition of mitochondrial ATP transport 
Accumulation of Pink1 in response to OXPHOS inhibitors in Figure 4 was concurrent 
with decreased mitochondrial ATP levels and largely unchanged cellular ATP amounts. It 
was reasoned that an altered ATP transport rate might also affect the overall energy state 
of the cell, influencing quality control reactions. Therefore, cells were treated with 
atractyloside, an inhibitor of the ADP/ATP carrier in the inner mitochondrial membrane 
(Figure 19). First, atractyloside treatment alone did not result in elevated cellular Pink1 
levels. Secondly, atractyloside did not interfere with Pink1 accumulation when cells were 
simultaneously exposed to atractyloside and the OXPHOS inhibitors. Thus, the observed 
increase in Pink1 levels indeed represented a mitochondria-specific event. 
 
Taken together, an increase in the cellular levels of Pink1 was only observed under 
mitochondrial but not cellular stress conditions. 
Figure 18*: Effect of 
tunicamycin on cellular levels 
of Pink1 and BiP. 
(A) Cells were incubated with 
tunicamycin (Tm) at the 
indicated concentrations for 
16 h and total cell lysates 
analyzed by SDS-PAGE and 
Western blot as above.  
(B) Cells were treated with 
tunicamycin at the 
concentrations indicated for 
16 or 24 h and total cell lysates 
analyzed as above, using an 
antibody against the ER 
chaperone BiP/Grp78.  
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5.4 Pink1 levels in muscle tissue of a COX8A patient 
In all experiments described so far, Pink1 protein levels were monitored in the time frame 
of hours upon induction of an acute stress condition. By contrast, there are pathological 
conditions, in which mitochondrial function is permanently impaired due to a genetic 
defect. In a specific case, a homozygous splice-site mutation in the COX8A gene, encoding 
the smallest nuclear-encoded complex IV subunit was shown to cause a severe 
neurological disorder termed Leigh-like syndrome and epilepsy (Hallmann, Kudin et al., 
2016). While functional consequences of the COX8A mutation, including reduced levels 
of complex IV were characterized in detail by Hallmann et al., native PAGE analysis is 
shown here to illustrate the effect of the mutation. 
 
To assess the effect of the COX8A mutation on total levels of complex IV mitochondrial 
fractions isolated from muscle biopsies of the COX8A patient and a healthy control, were 
analyzed by native PAGE and Western blot (Figure 20A). Antibodies specific for the 
complex IV subunits COX1, COX4 and COX5a all recognized a complex with an 
apparent relative molecular mass of 250 kDa, suggesting that this signal corresponded to 
the fully assembled complex IV. Compared to the control, the signal intensity was 
strongly reduced in the patient sample. This observation illustrates, that the COX8A 
mutation results in a severely decreased level of the entire complex IV. By comparison, 
levels of the succinate dehydrogenase complex (complex II), detected by an antibody 
Figure 19*: Effect of 
atractyloside on Pink1 
accumulation. Cells were 
treated for 16 h as above 
but in the presence or 
absence of the ADP/ATP 
translocase inhibitor 
atractyloside at 200 µM. 
Total cell lysates were 
analyzed as above. 
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against the complex II subunit A (SDHA), were similar in patient and control sample. This 
observation confirmed a complex IV-specific effect of the mutation.  
 
 
Figure 20: BN-PAGE analysis of mitochondrial fractions from skeletal muscle of a COX8A patient and 
healthy control. (A) Mitochondrial fractions from muscle biopsies were analyzed by BN-PAGE or standard 
SDS-PAGE and Western blot. Antibodies against the complex IV subunits COX1, COX4 and COX5A and 
the complex II subunit SDHA as a control were used. C: control, P: patient. (B) Complex IV levels in patient 
and control mitochondria. The major BN-PAGE signals for COX1, representative for complex IV, and 
SDHA in (A) were quantified. The signal intensities for COX1, normalized to SDHA are shown relative to 
the control. Results represent the mean of three experiments and the error bar indicates the standard error of 
the mean (SEM). This figure was published in (Hallmann et al., 2016). 
 
Quantification of the native PAGE signals for COX1, normalized to SDHA signals, 
revealed a residual complex IV level of 18 % in mitochondrial fractions isolated from the 
patient tissue, compared to the control (Figure 20B). Notably, antibodies against COX1 
and COX4 recognized two additional complexes of around 480 and 720 kDa, respectively, 
in control mitochondria. These signals putatively represent high molecular weight 
complexes, comprising complex IV and other respiratory chain complexes. Strongly 
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reduced levels of complex IV due to the COX8A mutation were shown to result in a severe 
isolated complex IV deficiency (Hallmann et al., 2016). In order to assess if this defect 
had an effect on Pink1 levels, total homogenates from patient and control skeletal muscle 
tissue were analyzed by SDS-PAGE and Western blot (Figure 21). As compared to total 
cell extracts from SH-SY5Y cells, exposed to CCCP for 16 h, the 64 kDa full-length form 
of Pink1 was not detectable in patient or control sample. Interestingly, a faint band 
corresponding to the 53 kDa processed Pink1 species, was detected in muscle 
homogenates of patient and control, respectively. 
 
In conclusion, a genetic complex IV deficiency did not result in elevated levels of Pink1. 
 
 
5.5 Import and processing of Pink1 
The existence of two forms of Pink1, the 64 kDa full-length (FL) and the 
53 kDa processed form (PF), is a striking characteristic of Pink1. Thus, the import and 
processing events converting Pink1-FL into Pink1-PF and the differential behavior of both 
forms were addressed in the following.  
 
5.5.1 Import of Pink1 into PARL-deficient mitochondria 
Processing of Pink1 by different mitochondrial proteases, including the presenilin-
associated rhomboid-like protease (PARL) has previously been reported (Deas, Wood et 
al., 2010b, Greene et al., 2012). To revisit PARL-mediated processing of Pink1, in vitro 
Figure 21: Pink1 levels in muscle tissue 
of a COX8A patient and a healthy 
control. Total homogenates from muscle 
biopsies were analyzed by SDS-PAGE and 
Western blot. SH-SY5Y cells exposed to 
10 µM CCCP for 16 h were analyzed as a 
control. 
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import of [35S]-methionine/cysteine-labeled full-length Pink1 into mitochondria isolated 
from homozygous PARL-deficient (PARL -/-) mouse embryonic fibroblasts (MEF) and 
corresponding wild-type cells was conducted (Figure 22).  
 
 
Figure 22: In vitro import of Pink1 into mitochondria from PARL-deficient cells or control cells. 
[35S]-methionie/cysteine-labeled Pink1 was incubated with energized mitochondria isolated from PARL -/- 
mouse embryonic fibroblasts or corresponding wild-type cells, for the times indicated. Where indicated, Dy 
was dissipated prior to the import reaction. Re-isolated mitochondria were analyzed by SDS-PAGE and 
digital autoradiography. 
 
When the Pink1-FL protein was incubated with energized wild-type mitochondria in the 
presence of Δψ, it associated with mitochondria and two protein bands, one of about 
53 kDa and another of about 44 kDa, accumulated over time (Figure 22, lanes 1-4). While 
the 44 kDa fragment was also detectable in the reticulocyte lysate (Figure 22, lane 17) and 
therefore likely represents an abnormal translation product, the 53 kDa band corresponds 
to the major processing product Pink1-PF. The 64 kDa Pink1 precursor likewise 
associated with wild-type mitochondria depleted of Δψ. The formation of the 53 kDa 
Pink1-PF was reduced in depolarized mitochondria, as compared to energized 
mitochondria, but not completely abolished (Figure 22, lanes 5-8). When the 64 kDa 
Pink1 precursor was incubated with polarized PARL-deficient mitochondria, another 
major Pink1 fragment of about 60 kDa, putatively representing the MPP cleavage product 
and PARL substrate, accumulated over time. Notably, a faint signal corresponding to the 
53 kDa Pink1-PF was also detected, albeit at a lower intensity compared to polarized 
wild-type mitochondria (Figure 22, lanes 9-12). In PARL-deficient mitochondria depleted 
of Dy, the 60 kDa fragment was not detectable, indicating that generation of this fragment 
requires the presence of an inner membrane potential. Importantly, a Pink1 species 
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indistinguishable from the 53 kDa Pink1-PF was generated in these mitochondria, at levels 
very similar to depolarized wild-type mitochondria.  
 
Taken together, generation of Pink1-PF was not strictly dependent on the presence of a 
Dy. Moreover, a fragment that was indistinguishable from Pink1-PF was generated in 
mitochondria isolated from PARL -/- cells, which were reported to have no detectable 
PARL mRNA (Cipolat, Rudka et al., 2006). Thirdly, the effect of the PARL deficiency on 
Pink1 processing was restricted to polarized mitochondria, as in depolarized mitochondria 
from both wild-type and PARL -/- cells, similar levels of the apparent Pink1-PF fragment 
were detected. 
 
5.5.2  Membrane association of full-length and processed forms of Pink1  
As a consequence of its proteolytic cleavage within the hydrophobic transmembrane 
domain (see Figure 1A), the 53 kDa processed Pink1 fragment may be less firmly 
associated with or integrated into the OMM than its 64 kDa full-length precursor. To 
address the membrane interaction properties of both Pink1 species, alkaline extraction was 
performed after in vitro import of radiolabeled full-length Pink1 into isolated HeLa 
mitochondria (Figure 23). During alkaline extraction, proteins that stably interact with 
membranes remain in the pellet fraction, while peripheral membrane proteins are found in 
the supernatant. Even under harsh conditions, at pH 12,about 93 % of Pink1-FL remained 
in the particulate, membrane-associated fraction (Figure 22, lane 4). By contrast, the 
amount of processed Pink1 in the pellet declined at pH 11.5 and Pink1-PF started to be 
detectable in the supernatant. At pH 12, only about 46 % of Pink1-PF remained in the 
pellet. As a control, immunodetection of the mitochondrial proteins MPP, VDAC 
(voltage-dependent anion channel) and Smac was performed. MPP and Smac, as soluble 
proteins of the matrix and intermembrane space compartment, respectively, were already 
detectable in the supernatant at pH 7.3. By contrast, the integral outer membrane protein 
VDAC resisted the extraction procedure almost entirely. In conclusion, Pink1-PF was less 
strongly membrane associated, compared to Pink1-FL in this assay.  
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Figure 23: Sensitivity of newly imported [35S]-Pink1 to alkaline extraction. Following in vitro import of 
radiolabeled Pink1 into isolated HeLa mitochondria for 40 min, mitochondria were subjected to alkaline 
extraction in 0.1 M Na2CO3 at the indicated pH. Samples were separated into pellet (P) and supernatant (SN) 
at 100,000 x g and analyzed by SDS-PAGE and digital autoradiography. As a control, immunodecoration of 
the endogenous mitochondrial proteins MPP, VDAC and Smac was performed. This figure was published in 
(Fedorowicz, de Vries-Schneider et al., 2014). 
 
5.5.3 Re-translocation of processed Pink1 to the cytosolic fraction 
A variation of the radioactive in vitro import assay was utilized, to follow the fate of 
newly generated Pink1-PF. To this end, after completion of the import reaction in 
polarized mitochondria, re-isolated, intact mitochondria were further incubated in the 
presence or absence of Δψ and then separated into mitochondrial and cytosolic fractions 
(Figure 23). In the presence of Δψ a fraction of about 6 % of Pink1-PF was detected in the 
soluble fraction after four minutes, and the intensity of this signal slightly increased over 
time (Figure 24 lanes 5-8). By contrast, when mitochondria were depleted of Δψ, 
Pink1-PF was only detected in mitochondrial fractions at all time points tested. Although 
in the presence of Δψ, a faint signal for Pink1-FL was also visible in the supernatants, the 
relative amount, judged by Pink1-FL signals in the pellet fractions, was lower compared to 
Pink1-PF. The integrity of mitochondrial membranes over the time period of the 
translocation assay was assessed by immunodetection of the soluble mitochondrial 
proteins MPP and Smac. Both proteins were exclusively present in the mitochondrial 
fractions, indicating that the Pink1-PF signal in the soluble fraction did indeed reflect 
re-translocation of the protein and was not due to disruption of the mitochondrial 
membranes. Transferred to the cellular situation, this observation is consistent with re-
translocation of a fraction of Pink1-PF from mitochondria to the cytosol. 
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Figure 24: Release of newly imported Pink1 from mitochondria. Following in vitro import of 
radiolabeled Pink1 into energized isolated HeLa mitochondria for 40 min, mitochondria were re-isolated and 
further incubated for the times indicated. Where indicated, Δψ was dissipated after completion of the import 
reaction. At the time points indicated, samples were separated into mitochondrial pellets and soluble 
fractions at 12,000 x g. Proteins were separated by SDS-PAGE and detected by digital autoradiography, 
followed by control immunodetection of the mitochondrial proteins MPP and Smac.  
 
5.5.4 Effect of OXPHOS inhibitors on Pink1 import 
According to the current model, import of Pink1 into mitochondria and therefore 
indirectly processing of Pink1 by mitochondrial-resident proteases is dependent on Dy. By 
this mechanism, Pink1-FL is thought to accumulate at depolarized mitochondria. Thus, it 
was investigated next, if the accumulation of Pink1 in response to OXPHOS inhibitors 
observed in Figure 4 was the result of diminished Pink1 import and processing. 
Mitochondria isolated from SH-SY5Y cells were treated with the respective OXPHOS 
inhibitors prior to import of [35S]-methionine/cysteine-labeled Pink1 as above 
(Figure 25A). Under control conditions, the 53 kDa Pink1-PF accumulated from 5 to 40 
minutes of incubation. By contrast, the formation of Pink1-PF was completely abolished 
in mitochondria pre-treated with CCCP or antimycin A (Figure 25A, lanes 3-6). 
Furthermore, pre-treatment with either oligomycin or rotenone alone resulted in a slightly 
reduced formation of Pink1-PF, as compared to control conditions, but as opposed to 
mitochondria treated with CCCP or antimycin A, the processed fragment was clearly 
generated (Figure 25A, lanes 7-10). By contrast, when mitochondria were incubated with 
a combination of oligomycin and rotenone prior to import, Pink1-PF was not detectable 
even after 40 minutes of import (Figure 25A, lane 12). Notably, in mitochondria treated 
with CCCP or the respective OXPHOS inhibitors, a diminished accumulation of the 
53 kDa Pink1-PF correlated with an increased formation of yet another Pink1 fragment of 
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about 56 kDa. In these mitochondria, the formation of this putative processing 
intermediate showed a different kinetics, since compared to the 53 kDa form of Pink1, it 
was already detected after five min. To a smaller extent, the 56 kDa Pink1-fragment was 
also detectable after 40 min of import under control conditions. 
 
To monitor the effect of the pre-treatment on Δψ, mitochondria incubated under the same 
conditions were subjected to TMRE staining and measurement of TMRE fluorescence 
(Figure 25B). Similar to the results obtained in intact cells in 4.1.1, Δψ was strongly 
diminished under all conditions tested with the exception of oligomycin treatment, which 
resulted in an increased Δψ, compared to mitochondria incubated under control 
conditions.  
 
Taken together, two observations from the import experiment strongly argue against a 
strict correlation between an intact Δψ and Pink1 import and processing: First, a 
considerable amount of Pink1-PF was still formed when Δψ was strongly diminished by 
the complex I inhibitor rotenone. Secondly, while Δψ was either increased or strongly 
reduced in mitochondria pre-treated with oligomycin or rotenone, respectively, the 
efficiency of Pink1 processing was similar under both conditions. Transferred to the 
cellular level, impaired import and processing of Pink1 were likely not the only reason for 
an increase in protein levels of Pink1-FL.  
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Figure 25: In vitro import of Pink1 and Δψ  measurements in mitochondria treated with inhibitors of 
oxidative phosphorylation. (A) In vitro import of Pink1. Mitochondria isolated from SH-SY5Y cells were 
incubated with EtOH (control), 1 µM CCCP, 8 µM antimycin A, 20 µM oligomycin, 0.5 µM rotenone or a 
combination of 20 µM oligomycin and 0.5 µM rotenone for 5 min, followed by import of radiolabeled Pink1 
for 5 or 40 min, respectively. After re-isolation of mitochondria, proteins were separated by SDS-PAGE and 
detected by digital autoradiography. (B) Measurement of Δψ in isolated mitochondria. Mitochondria treated 
as in (A) were incubated with 1 µM TMRE for 30 min and TMRE fluorescence was measured in a 
microplate reader. TMRE fluorescence intensities are shown relative to EtOH-treated control cells. Results 
represent the mean of three independent experiments and two technical replicates per experiment. Error bars 
indicate the standard error of the mean (SEM). 
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5.6 Degradation of Pink1 under normal and stress conditions 
In general, the energetic state of mitochondria affects both import and degradation of 
mitochondrial proteins (Voos, 2013). Since the import experiments shown so far, revealed 
only a partial effect of the mitochondrial membrane potential on import and processing of 
Pink1, degradation of the protein was monitored. 
 
5.6.1 Cellular turnover of Pink1 
To assess Pink1 turnover on the cellular level, radioactive pulse/chase-labeling and 
subsequent immunoprecipitation was conducted, using Pink1-FLAG transiently expressed 
in SH-SHSY cells (Figure 26). Under these experimental conditions, both the 64 kDa 
Pink1-FL and the 53 kDa Pink1-PF were detectable by autoradiography (Figure 26A). At 
the starting point of the chase period (t=0) the 53 kDa Pink1-PF accounted for about 45 % 
of the total cellular amount of Pink1.  
 
Over the course of 5 h incubation under control conditions, both Pink1-FL and Pink1-PF 
were gradually degraded to about 26 % and 36 %, respectively, relative to the starting 
value. Quantitative analysis of the degradation experiment resulted in half-life values of 
approximately 125 min for full-length Pink1 and 175 min for the processed form of Pink1 
(Figure 26B). To monitor the effect of mitochondrial perturbation on Pink1 stability, cells 
were exposed to CCCP during the chase period. The resulting turnover rates for both 
full-length and processed forms were very similar to those in untreated cells. Small 
differences in the relative ratios between full-length and processed forms under control 
and CCCP conditions, respectively, are consistent with a reduced processing of Pink1 in 
the absence of Δψ as observed in Pink1 import experiments described above (see 
Figures 22 and 25). In conclusion, changes in Δψ did not affect the overall cellular 
degradation rates of Pink1. By comparison, treatment of cells with the proteasome 
inhibitor MG132 during the chase period resulted in a significantly increased stability of 
the processed form of Pink1. However, turnover of PINK1-FL was only marginally 
affected, extending its half-life from 125 to 180 min. This indicates, that at least the 
processed form of Pink1 is degraded by the proteasome. 
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Figure 26: Cellular degradation of overexpressed [35S]-labeled Pink1-FLAG. SH-SY5Y cells transiently 
expressing Pink1-FLAG were subjected to [35S]-Met/Cys pulse labeling for 30 min and chase incubation 
with excess cold Met/Cys for the times indicated. Following immunoprecipitation of Pink1-FLAG, proteins 
were separated by SDS-PAGE and detected by digital autoradiography. (A) Representative autoradiograms 
of pulse/chase experiments, with chase under normal conditions and in the presence of 10 µM CCCP or 
10 µM MG132. FL and PF indicate the 64 kDa full-length Pink1 and the 53 kDa processed form, 
respectively. (B) Quantification of cellular Pink1 degradation. Amounts of Pink1-FL and Pink1-PF are given 
as percentage of the respective initial Pink1 amount at t=0. Results represent the mean of three independent 
experiments per condition tested. Error bars indicate the standard error of the mean (SEM). 
 
5.6.2 Mitochondrial turnover of Pink1 
Reasoning that Pink1 at least partially enters mitochondria, it may be degraded by 
mitochondrial proteases as was previously postulated (Greene et al., 2012). To address this 
possibility, radiolabeled Pink1 was imported into isolated SH-SY5Y mitochondria for 
40 min. After re-isolation of mitochondria the fate of the different Pink1 fragments was 
followed over a period of 4 h (Figure 27). At the start of the degradation time (t=0) both, 
the Pink1-FL and the Pink1-PF species were detected while Pink1-FL was the more 
abundant form, similar to the cellular degradation assay. As evident by the respective 
signal intensities, 20 % of the total mitochondria-associated Pink1 had been processed to 
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Pink1-PF during the import time (Figure 27A, lane 1). In energized mitochondria, the total 
amount of Pink1 declined by about 40 % over the 4 h course of the degradation 
experiment (Figure 27C). The relatively constant apparent amounts of Pink1-PF detected 
during this time are consistent with a continuing conversion of mitochondria-bound or 
already imported Pink1-FL to Pink1-PF. A very similar degradation rate was obtained, 
when Δψ was dissipated by the addition of CCCP after completion of the import reaction 
(Figure 27D). Hence, the presence of Δψ had no detectable effect on mitochondrial 
degradation of Pink1. Notably, total degradation reactions were analyzed in this 
experiment, to account also for the fraction of Pink1 that was shown to be released from 
mitochondria in the translocation assay (see Figure 24). The processed form Pink1-PF was 
previously postulated to be the main target of mitochondrial proteases (Greene et al., 
2012). To assess the degradation of the processed Pink1 fragment alone, by circumventing 
the continuing conversion of Pink1-FL to Pink1-PF, the mutant Pink1Δ103 was used as a 
substrate in the degradation assay as above (Figure 26E). Pink1Δ103 mimics the proposed 
PARL-cleavage product (Deas et al., 2010a) and associates with mitochondria similar to 
the wild-type protein in vitro (Becker et al., 2012a). However, the degradation rate of 
about 40 % over 4 h of incubation was almost identical to the value obtained for combined 
Pink1-FL and Pink1-PF signals in the degradation assay with wild-type Pink1. In 
conclusion, the processed form of Pink1 did not show a higher sensitivity to degradation 
by mitochondrial proteases compared to full-length Pink1.  
 
In a next approach, the degradation assay was repeated under ATP depletion conditions, to 
assess the involvement of ATP-dependent processes in the observed reduction of the 
Pink1 signal over time (Figure 27F). The resulting degradation rate of about 40 % over 4 h 
was virtually indistinguishable from the value obtained in energized mitochondria, arguing 
against a role of one of the ATP-dependent proteases of the mitochondrial matrix or inner 
membrane compartment in the degradation of Pink1. 
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Figure 27: Mitochondrial degradation of newly imported [35S]-Pink1. After in vitro import of [35S]-
Pink1 into energized isolated SH-SY5Y mitochondria, a degradation assay was performed as described in 
2.4.6. Total samples were analyzed by SDS-PAGE and digital autoradiography. For quantification, the 
combined initial amount of full length (FL) and processed (PF) [35S]-Pink1 was set to 100 % and results for 
each time point calculated as percentage of the initial amount. Percentages of FL and PF for each time point 
are indicated by different grey scale. Results represent the mean of three independent experiments per 
condition tested. Error bars indicate the standard error of the mean (SEM). (A, B) Representative 
autoradiograms for mitochondrial degradation of Pink1 under normal conditions (A) or after depletion of 
Δψ (B). (C) Degradation under normal conditions. (D) Degradation after depletion of Δψ after completion of 
the import reaction. (E) Degradation of [35S]-Pink1Δ103 (F). Degradation of [35S]-Pink1 in mitochondria 
depleted of ATP by apyrase treatment and the addition of oligomycin after completion of the import 
reaction.  
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Taken together, the results of the degradation assays imply, that the vast accumulation of 
Pink1, observed upon depletion of Δψ, is not due to a diminished cellular or mitochondrial 
turnover of the protein. Moreover, the processing state of Pink1 did not determine its 
sensitivity towards degradation.  
 
5.7 Regulation of Pink1 gene expression 
If the accumulation of Pink1 under mitochondrial stress conditions is not the result of a 
decrease in processing and turnover of the protein, cellular amounts of Pink1 must be 
regulated on another level. Thus, the requirement of protein biosynthesis for Pink1 
accumulation was assessed. 
 
5.7.1 Effect of transcription and translation inhibitors on Pink1 protein 
levels 
In a first approach, SH-SY5Y cells were exposed to the inhibitors of oxidative 
phosphorylation as before, but in the presence or absence of the translation inhibitor 
cycloheximide (Figure 28).  
 
 
Figure 28: Effect of cycloheximide and actinomycin D on Pink1 protein expression.  
(A) Effect of translation inhibition on Pink1 expression. SH-SY5Y cells were treated with DMSO/EtOH 
(control), CCCP, oligomycin or antimycin A at concentrations described for Figure 4 for 16 h but in the 
presence or absence of 50 µg/ml cycloheximide. (B) Effect of transcription inhibition on Pink1 expression. 
Cells were incubated with DMSO/EtOH or CCCP for 16 h as above but in the presence or absence of 
5 µg/ml actinomycin D.  
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As shown in Figure 28A, accumulation of Pink1 in response to CCCP, oligomycin or 
antimycin A was almost completely blocked by cycloheximide. This observation implies, 
that the de novo synthesis of Pink1 molecules is indispensible for an increase in cellular 
Pink1 levels. To further elucidate, which step of protein biosynthesis is crucial for Pink1 
accumulation, actinomycin D was used to inhibit transcription during exposure of cells to 
CCCP. As evident from Figure 28B, Pink1 accumulation was almost completely abolished 
in the presence of actinomycin D. This observation indicates the regulation of Pink1 
protein amounts on the transcriptional level. 
 
5.7.2 Pink1 mRNA levels in response to OXPHOS inhibitors 
In order to verify the observations from actinomycin D experiments, quantitative real-time 
PCR (qRT-PCR) was performed. In detail, Pink1 mRNA amounts, relative to mRNA 
levels of GAPDH as a control were analyzed. After exposure of cells to CCCP, 
antimycin A or oligomycin for 8 h, an approximately two-fold increase in Pink1 mRNA 
expression, relative to samples treated with the respective compound for 0.5 h was 
observed (Figure 29 A-C). Relative amounts of Pink1mRNA further increased in cells 
treated with CCCP or antimycin A, reaching approximately four-fold of the starting value 
(0.5 h). A slight increase in Pink1 mRNA expression was also observed between 8 and 
16 h of oligomycin treatment, respectively. After 24 h of exposure to all three inhibitors, 
Pink1 mRNA levels started to decline. Compared to the other inhibitors, Pink1 mRNA 
amounts measured in cells treated with the complex 1 inhibitor MPP+ were lower, 
reaching a maximum of approximately 1.5-fold after 16 h (Figure 29D). 
 
In conclusion, the sensitivity of Pink1 accumulation to an inhibition of protein 
biosynthesis together with elevated Pink1 mRNA levels in response to mitochondrial 
perturbations imply, that cellular amounts of Pink1 are determined by transcriptional 
regulation of PINK1 gene expression.  
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Figure 29: Analysis of Pink1 mRNA levels by qRT-PCR. After treatment of cells with 10 µM CCCP, 
50 µM oligomycin, 200 µM antimycin A or 2.5 mM MPP+, Pink1 mRNA levels were determined by 
quantitative RT-PCR and normalized to mRNA levels of GAPDH for each sample. Results are shown 
relative to mRNA levels in cells exposed to the respective compound for 0.5 h and represent the mean of two 
technical replicates. mRNA measurements were performed by Kerstin Hallmann (Life and Brain Center, 
University of Bonn). 
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5.7.3 Candidate regulators of Pink1 transcription  
Several factors have previously been discussed in the context of Pink1 gene expression. 
One candidate, the transcription factor c-Fos (Gomez-Sanchez, Gegg et al., 2014), is 
responsive to elevated intracellular calcium levels. To revisit calcium-dependent 
regulation of Pink1 expression, SH-SY5Y cells were treated with thapsigargin at different 
concentrations. By inhibiting the sarcoplasmic/endoplasmic Ca2+ ATPase (SERCA), 
thapsigargin prevents calcium uptake into intracellular storage compartments, which 
results in an increase in cytosolic Ca2+-levels (Lytton, Westlin et al., 1991, Thastrup, 
Cullen et al., 1990). However, no increase in Pink1 protein levels was detected after 
exposure of cells to thapsigargin even at high concentrations (Figure 30). This observation 
implies, that intracellular Ca2+-levels do not affect Pink1 expression under the conditions 
tested here.  
 
 
 
 
Another previous study, examining the Pink1 promoter, proposed the transcription factor 
NF-kB (nuclear factor kappa-light-chain-enhancer of activated B-cells) as an activator of 
Pink1 gene expression (Duan, Tong et al., 2014). Thus, the effect of three different 
inhibitors of NF-kB signaling, NG25, BI605906 and MLN4924 on Pink1 induction in 
response to CCCP was tested. BI605906 prevents activation of NF-kB signaling by 
inhibiting the I-kB kinase (IKK) complex, which usually phosphorylates the inhibitor I-kB 
under inductive conditions, marking it for ubiquitination and proteasomal degradation. 
MLN4924 inhibits both the canonical and non-canonical activation of NF-kB by affecting 
the proteasomal degradation of the I-kB inhibitor. NG25 is an inhibitor of the TAK1 
Figure 30*: Effect of 
thapsigargin on Pink1 
expression. SH-SY5Y cells were 
treated with the inhibitor of the 
sarco/endoplasmatic reticulum 
Ca2+-ATPase (SERCA) 
thapsigargin, at 0.25 to 5 µM or 
with DMSO or 10 µM CCCP as 
controls for 16 h. Total cell 
lysates were analyzed by SDS-
PAGE and Western blot. 
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kinase, which is involved in the intracellular propagation of NF-kB-related signaling 
events. As shown in Figure 31, MLN4924 and, to a smaller extent, BI605906 led to a 
decrease in Pink1 levels after CCCP-treatment (by about 30 % for MLN4929) but did not 
completely abolish Pink1 induction. By comparison, Pink1 induction in response to CCCP 
was slightly increased in the presence of NG25.  
 
In summary, both inhibitors with an effect on I-kB reduced Pink1 expression levels, 
indicating at least a partial dependence of Pink1 induction on regulation via the NF-kB 
signaling pathway.  
 
 
 
Through mediating degradation of the endogenous NF-kB inhibitor Ik-B, the ubiquitin- 
proteasome system is directly involved in NF-kB signaling. Accordingly, the proteasome 
inhibitior MG132 blocks NF-kB activation (Lee & Goldberg, 1998). Therefore, MG132 
was used as an alternative way to study involvement of NF-kB in transcriptional 
regulation of Pink1 (Figure 32). Pink1 induction in response to CCCP, oligomycin or 
antimycin A was almost completely abolished in the presence of the proteasome inhibitor. 
The accumulation of the 53-kDa Pink1-PF observed after MG132 treatment is in 
consistence with the notion, that the processed Pink1 fragment is a target of the 26S 
proteasome, as was observed in the cellular degradation assay (see Figure 26) and has 
been described previously (Lin & Kang, 2008).  
 
Figure 31*: NF-kB 
dependence of Pink1 
expression. Cells were 
pre-treated with 
inhibitors of NF-kB 
signaling MLN4924, 
BI605906 or NG25 for 
2 h followed by 16 h 
incubation in the 
presence of the 
respective inhibitor 
and 10 µM CCCP.  
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Taken together, the effect of specific NF-kB inhibitors as well as the strong inhibitory 
effect of MG132 on the induction of Pink1 are consistent with an involvement of NF-kB 
signaling in Pink1 gene expression under mitochondrial stress conditions. 
 
 
 
5.8 Association of wild-type and mutant α-synuclein with 
mitochondria 
Albeit its predominantly cytosolic localization, several studies have demonstrated 
α-synuclein to be localized in or at mitochondria (Devi et al., 2008, Li et al., 2007). An 
intra-mitochondrial localization of the nuclear-encoded α-synuclein would require its 
insertion into or translocation over the mitochondrial membranes. To directly address this 
hypothesis, an in vitro import assay of [35S]-Met/Cys-labeled wild-type and mutant (A30P 
and A53T) α-synuclein was performed (Figure 33). The two pathogenic point mutations in 
α-synuclein, A30P and A53T, respectively, are associated with autosomal-dominant PD 
(Klein & Westenberger, 2012). Mitochondrial malate dehydrogenase 2 (Mdh2), which is 
imported into the mitochondrial matrix via the TOM and TIM23 translocase complexes, 
was used as a control (Figure 33). 
 
Figure 32: Effect of MG132 on Pink1 
expression. Cells were treated with 
CCCP, oligomycin or antimycin A as 
described for Figure 4, but in the 
presence or absence of the proteasome 
inhibitor MG132 at 10 µM for 8 h. Total 
cell lysates were analyzed by 
SDS-PAGE and Western blot. Pink1-PF 
is indicated with an asterisk. 
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Figure 33: In vitro import assay with [35S]-labeled α -synuclein. In vitro import of [35S]-Met/Cys-labeled 
Mdh2 and either wild-type a-synuclein, α -synucleinA30P or a-synucleinA53T into energized isolated HeLa 
mitochondria for 2 or 15 minutes was performed under standard conditions. Where indicated, Δψ was 
dissipated prior to the import reaction. Protease-accessible proteins were digested by incubation with 
100 µg/ml trypsin after the import (lower panel). Mock samples contained no mitochondria. Following re-
isolation of mitochondria, proteins were separated by Tricine-SDS-PAGE and detected by digital 
autoradiography. This figure was published in (Guardia-Laguarta, Area-Gomez et al., 2014). 
 
When the Mdh2 precursor protein was incubated with energized isolated HeLa cell 
mitochondria, it associated with mitochondria. The appearance of a second band, 
representing the mature form after cleavage of the presequence by the matrix processing 
peptidase (MPP), was observed after 15 min of import (Figure 33 lanes 4-6). In 
consistence with import into the mitochondrial matrix, processing of Mdh2 was dependent 
on the mitochondrial membrane potential (Δψ) (Figure 33, lanes 7-9) and the processed 
Mdh2 but not the full-length form was resistant to trypsin treatment of mitochondria 
re-isolated after import (Figure 33, lanes 1-6, lower panel). As compared to the Mdh2 
control, wild-type α-synuclein also associated with mitochondria and this association was 
reduced in the absence of Δψ. However, neither an increase in mitochondria-bound 
α-synuclein over time, nor the appearance of a cleaved fragment was observed 
(Figure 33, lanes 1 and 4). While a fraction of the mitochondria-associated α-synuclein 
was apparently resistant to protease treatment a similar amount of trypsin-resistant 
a-synuclein was detected in the absence of mitochondria in “mock” samples (Figure 33, 
lane 10). This observation may be explained by aggregation of a fraction of α-synuclein, 
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which would reduce the accessibility of the protein to trypsin. The α-synuclein aggregates 
would then sediment during re-isolation of mitochondria by centrifugation.  
 
As compared to the wild-type protein, less α-synucleinA30P associated with mitochondria, 
while the binding efficiency of α-synucleinA35T was slightly increased over the WT 
protein. Moreover, binding of both mutant proteins was partially dependent on Δψ and a 
fraction of a-synucleinA30P and a-synucleinA53T, respectively, was resistant to trypsin even 
in the absence of mitochondria, similar to the wild-type protein (Figure 33, lanes 7-12). 
 
Most mitochondrial proteins require the TOM complex for insertion into or crossing of the 
outer mitochondrial membrane (OMM) (Becker et al., 2012b). Thus, in a second 
approach, isolated mitochondria were incubated with proteinase K (PK) to digest the 
cytosol-exposed peripheral receptors Tom20 and Tom70 prior to in vitro import as above 
(Figure 34). Import of Mdh2, as evident by the appearance of the processed form, was 
strongly reduced even at 5 µg /ml PK. By contrast, the binding of both α-synuclein and the 
Mdh2 precursor to mitochondria was unaffected by PK pre-treatment (Figure 34, lanes 1-
8). This observation implies, that a-synuclein association with mitochondria does not 
occur through the TOM receptors. In case of the Mdh2 control, import but not binding of 
the Mdh2 precursor was dependent on TOM receptors at the outer face of the OMM. The 
effect of the PK pre-treatment was confirmed by Western blot analysis of Tom70 and 
Tom40 (Figure 34, lower panel). According to their respective positions, the partially 
peripheral Tom70 receptor was readily cleaved by PK, while the pore-forming integral 
membrane protein Tom40 was digested only by a combination of pre- and post-treatment 
(Figure 34, lanes 5-8).  
 
In summary, WT and mutant α-synuclein associated with mitochondria in a Δψ-dependent 
manner. Since this binding was independent of TOM receptors and did not confer 
protease-resistance, α-synuclein is likely not imported into the mitochondrial membranes 
or matrix compartment.  
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Figure 34: Dependence of α-synuclein association with mitochondria on mitochondrial outer 
membrane receptors. Isolated mitochondria were incubated with proteinase K at the indicated 
concentrations (pre-treatment), prior to in vitro import of radiolabeled Mdh2 and α-synuclein for 15 min in 
the presence or absence of Δψ. Protease-accessible proteins were digested by treatment with 
100 µg/ml trypsin (post-tratment). After re-isolation of mitochondria, proteins were separated by 
Tricine-SDS-PAGE. Digital autoradiography and control immunodetection of the TOM subunits Tom40 and 
Tom70 is shown. 
 
  
6 Discussion 
 
75 
6 Discussion 
6.1 Pink1 accumulates upon specific mitochondrial 
perturbations  
The kinase Pink1 accumulates on the surface of defective mitochondria. This event 
represents a pivotal step in an organellar quality control pathway that mediates the 
removal of damaged mitochondria by mitophagy. The strong increase in cellular levels of 
Pink1 is an outstanding characteristic of this protein, seeking its equal among other 
mitochondrial components. According to current models, Pink1 is constitutively expressed 
at high levels, while steady-state amounts at healthy mitochondria are kept low by a rapid 
proteolytic turnover of the protein (Eiyama & Okamoto, 2015, Pickrell & Youle, 2015). 
Import of Pink1 into mitochondria and processing by mitochondrial proteases is proposed 
to be a prerequisite for its subsequent degradation. Thus, a reduction of the inner 
membrane potential (Δψ) and the concurrent inhibition of mitochondrial import would 
result in an accumulation of full-length Pink1 at the mitochondrial surface, which in turn 
would initiate the downstream mitophagy process. This rather elaborate mechanism is 
proposed to allow a rapid accumulation of Pink1 upon loss of Δψ, a major hallmark of 
mitochondrial damage (Eiyama & Okamoto, 2015, Pickrell & Youle, 2015). However, the 
proposed import/turnover model has its shortcomings. First, both full-length Pink1 (Pink1-
FL) and its major processing product (Pink1-PF) localize exclusively to the outer face of 
the OMM (Becker et al., 2012a) and secondly, it is still not clear which protease is 
responsible for the degradation of Pink1. I therefore aimed at elucidating the connection 
between mitochondrial dysfunction and the accumulation of Pink1 in my thesis. 
 
In my experiments, the increase in Pink1 protein levels was not strictly correlated with a 
reduction of Δψ, as was previously postulated (Matsuda et al., 2010, Narendra et al., 
2010b). By contrast, a significant up-regulation of Pink1 amounts concurrent with an 
increased Δψ was observed after exposure of cells to the mitochondrial F1/FO-ATPase 
inhibitor oligomycin. Conversely, treatment of cells with the complex I inhibitor MPP+ 
resulted in a decreased Δψ but failed to provoke an accumulation of Pink1. 
 
The inhibition of Δψ-dependent import, as a prerequisite for Pink1 degradation, has been 
postulated to account for the accumulation of Pink1-FL selectively at the surface of 
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depolarized mitochondria. However, the results from my in vitro import assay 
(Figure 25A) argue against this hypothesis. First, Pink1 import was not strictly dependent 
on Δψ and secondly, inhibition of Pink1 import in vitro did not necessarily correlate with 
elevated cellular amounts of Pink1. Although treatment of mitochondria with rotenone 
resulted in a strongly reduced Δψ, a considerable amount of Pink1 was still imported and 
processed. This observation is in line with the previously published finding, that Pink1 
import and generation of Pink1-PF in vitro is only partially abolished in depolarized 
mitochondria (Becker et al., 2012a). Moreover, while rotenone and oligomycin inhibited 
in vitro import of Pink1 to a similar degree, oligomycin but not rotenone caused elevated 
cellular Pink1 levels. When relating the results from the import experiment to cellular 
Pink1 levels, the different experimental conditions should be taken into account. While 
protein levels of Pink1 were determined in intact cells exposed to the OXPHOS inhibitors 
for several hours, isolated mitochondria were incubated with the respective compounds for 
five minutes prior to the import assay. Still, similar effects of CCCP, antimycin A and 
oligomycin on Δψ were measured under the respective conditions in intact cells and in 
vitro, arguing for comparable conditions in both assays. It should be noted that rotenone 
treatment is not compatible with assessing Δψ by TMRE staining of intact cells. Provided 
that the in vitro assay sufficiently reflects the cellular situation, the combined results from 
both experiments allow two conclusions on the accumulation of Pink1: 1) a reduced 
membrane potential is likely not the sole trigger for Pink1 accumulation and 2) Δψ-
dependent import is not the single mechanism responsible for the regulation of Pink1-FL 
amounts at the mitochondrial surface. Pink1 was furthermore proposed to form a complex 
with components of the TOM translocase at the surface of depolarized mitochondria. This 
association would allow a rapid re-import of the protein to rescue mitochondria from 
mitophagy (Lazarou, Jin et al., 2012). In the native PAGE experiments shown here, I 
found Pink1 present in two high molecular weight complexes of about 700 and 900 kDa, 
respectively, when it accumulated in response to CCCP (Figure 13). However, Pink1 did 
not co-migrate with the TOM component Tom40, arguing against complex formation 
between Pink1 and the outer membrane translocase. While this observation questions the 
model suggested by Lazarou et al. it is in line with another previous study examining 
Pink1 complexes by native PAGE (Becker et al., 2012a). As two of the known direct 
Pink1 substrates, Parkin and Mfn2, did also not co-migrate with Pink1, identifying the 
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actual complex constituents in future experiments may lead to the identification of novel 
Pink1 interaction partners. 
 
In my experiments, general cellular perturbations, exemplified by tunicamycin-induced 
ER protein stress and oxidative stress, collectively failed to elicit elevated levels of Pink1. 
The absence of an effect of atractyloside, an inhibitor of the mitochondrial nucleotide 
transporter further indicates that the overall cellular energy state is likely not involved in 
damage-related accumulation of Pink1. 
 
In the experiments shown here, enhanced amounts of Pink1 in response to OXPHOS 
inhibitors correlated well with reduced levels of mitochondrial proteins. Moreover, a 
potentially ubiquitinated species of Mfn2 concurrent with high levels of Pink1, may reflect 
Parkin-dependent ubiquitination of Mfn2 (Gegg et al., 2010). While both observations are 
consistent with Pink1/Parkin-mediated mitophagy, a direct confirmation for the initiation 
of mitophagy is missing. It should be noted that a reliable assay to detect mitophagy has 
not been described so far. Most methods assess the loss of mitochondrial proteins, as also 
observed here. However, removal of mitochondrial components may occur by several 
distinct processes. First, addition of specific ubiquitin chains by Parkin was shown to 
result in the proteasomal degradation of OMM proteins, including Mfn2, which in turn 
was crucial for mitophagy (Chan, Salazar et al., 2011). Secondly, so-called mitochondria-
derived vesicles (MDVs) were proposed to sequester components of the mitochondrial 
matrix and IMM for delivery to lysosomal degradation (Soubannier, McLelland et al., 
2012), and this process possibly involves Pink1 and Parkin (McLelland, Soubannier et al., 
2014). Thus, it remains to be clarified, if Pink1 accumulation under the conditions tested 
here did indeed result in autophagic elimination of mitochondria by mitophagy.  
 
6.2 Pink1 does not accumulate in response to mitochondrial 
protein stress 
Although being restricted to mitochondrial perturbations, Pink1 accumulation appears to 
occur only in response to a subset of mitochondrial insults. In my hands, potential 
mitochondrial protein stress generated either through ectopic expression of a destabilized 
model protein or by reducing the endogenous amount of the mitochondrial Hsp70 
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chaperone Mortalin, did not result in enhanced Pink1 levels. The first observation 
contradicts the previously published finding that the expression of a mitochondria-targeted 
aggregation-prone mutant OTC (ornithine carbamoyltransferase) causes the accumulation 
of Pink1 and mitophagy (Jin & Youle, 2013). This discrepancy may be due to different 
aggregation propensities or expression levels of the two model proteins. There are 
different explanations for the increased Pink1 levels upon expression of mutant OTC 
observed by Jin et al. First, accumulation of Pink1 could be a direct response to intra-
mitochondrial protein aggregates, as it is described for the protein-stress induced 
mitochondrial unfolded protein response in C.elegans (mtUPR, see below). Alternatively, 
the overexpression of an artificial aggregation-prone protein may indirectly cause 
mitochondrial damage, which in turn would lead to elevated Pink1 levels. In the latter 
case, Pink1 accumulation might occur through the same mechanism as the upregulation of 
Pink1 I observed upon inhibition of OXPHOS. Thus, determining if Pink1 accumulation is 
a direct or indirect effect of intra-mitochondrial protein aggregates will be an important 
cue for resolving a putative signaling mechanism responsible for the regulation of Pink1 
levels. Importantly, Jin et al. note that Pink1 accumulation occurred in the presence of an 
intact Δψ, supporting my present findings discussed above. Another study showed that the 
Mortalin knockdown phenotype in cells, namely increased susceptibility to intra-
mitochondrial proteolytic stress, mitochondrial fragmentation and reduced mitochondrial 
mass, could be rescued by overexpression of Pink1 and Parkin (Burbulla, Fitzgerald et al., 
2014). However, the authors did not examine levels of endogenous Pink1 in this context. 
Thus, although Pink1/Parkin-mediated mitophagy may in general counteract 
mitochondrial damage resulting from loss of Mortalin, it remains elusive if protein stress 
is a direct trigger for Pink1 accumulation and subsequent mitophagy. 
6.3 Inhibition of complex I or a genetic complex IV deficiency 
do not result in elevated Pink1 levels 
I have shown in my thesis, that inhibition of complex I (NADH-ubichinon-
oxidoreductase) with either rotenone or MPP+, a metabolic product of the PD-related 
neurotoxin MTPT (Singer et al., 1988), reduces both Δψ and mitochondrial ATP levels 
without promoting an accumulation of Pink1. This observation does not only challenge the 
current model of Δψ-dependent accumulation of Pink1 but prompts an intriguing 
hypothesis. The failure to elicit an accumulation of Pink1 by complex I inhibitors like 
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MTPT would also preclude a subsequent activation of the Pink1/Parkin-related quality 
control pathway, thereby contributing to the development of Parkinson’s disease, similar 
as defects or loss of Pink1 function contribute to hereditary PD (Valente et al., 2004). 
 
Apart from the short-term mitochondrial stress conditions caused by chemical treatment of 
cells described above, I also examined Pink1 levels under a condition of permanent 
mitochondrial dysfunction due to a genetic defect. In detail, I analyzed Pink1 levels in 
muscle tissue samples of a patient carrying a mutation in the gene encoding subunit 8A of 
respiratory chain complex IV (cytochrome c oxidase). Pink1 was not detectable under-
steady state conditions in this tissue. Notably, protein levels of complex IV as well as 
complex IV-dependent respiratory activity, measured in cultured fibroblasts of the same 
patient, were dramatically reduced (Hallmann et al., 2016). Thus, the COX8A mutation 
represents yet another condition, where severe mitochondrial dysfunction and Pink1 
accumulation are not correlated. However, it remains to be elucidated if COX8A-deficient 
cells do accumulate Pink1 upon treatment with OXPHOS inhibitors, or if Pink1 induction 
is altogether abolished in these cells. The lack of Pink1 accumulation observed under 
steady-state conditions also raises the question, if distinct stress-responses exist. Under 
short-term stress conditions accumulation of Pink1 at defective mitochondria and 
mitophagy may be beneficial. By contrast, permanent dysfunctions, exemplified by 
mutations in nuclear-encoded genes for respiratory chain components, affect the whole 
mitochondrial network. In the latter case, the removal of virtually the entire mitochondrial 
population would be deleterious. Intriguingly, a direct connection between a genetic 
respiratory chain defect and Parkinsonism was proposed only for a mutation in the 
nuclear-encoded cytochrome c (De Coo, Renier et al., 1999). A possible explanation is, 
that at least severe hereditary OXPHOS defects typically cause premature death and these 
patients simply do not reach the age of even early-onset PD (Schon & Przedborski, 2011). 
Although a connection between large-scale somatic mtDNA mutations and PD was 
reported (Bender et al., 2006), it remains to be elucidated if a lack of Pink1 accumulation 
contributes to the etiology of the disease in these cases, similarly as hypothesized above 
for complex I inhibition.  
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6.4 A fraction of processed Pink1 translocates to the cytosol 
Sequential proteolytic cleavage of the 64 kDa full-length Pink1 by MPP and PARL was 
previously proposed to generate the 53 kDa processed Pink1 fragment (Deas et al., 2010a, 
Greene et al., 2012). By analyzing in vitro import of Pink1 into PARL-deficient 
mitochondria, I confirmed here, that Pink1-PF is indeed generated by PARL. However, 
low levels of an apparently identical processed Pink1 species accumulating even in the 
absence of PARL, suggested an alternative, PARL-independent cleavage. In contrast to 
PARL-dependent processing, generation of this PARL-independent fragment was virtually 
unaltered in the absence of Δψ. However, regarding the low abundance of this fragment, 
the physiological relevance of a proposed alternative processing reaction is debatable. 
 
In all experiments analyzing Pink1 accumulation in cultured cells discussed so far, only 
the 64 kDa Pink1-FL was detectable by Western blot analysis, which is consistent with 
rapid proteasomal degradation of the 53 kDa Pink1-PF species (Lin & Kang, 2008). The 
previously described increase in endogenous Pink1-PF upon exposure of cells to the 
proteasome inhibitor MG132 was reproducible in my experiments. The highly sensitive 
radioactive in vitro import assay allowed following the fate of newly processed Pink1 
under steady-state conditions. First, the processed Pink1 fragment displayed a weaker 
membrane association compared to the full-length species, which may result from PARL-
mediated cleavage within the hydrophobic N-terminal domain (Deas et al., 2010a). 
Secondly, I was able to show that a fraction of Pink1-PF is released from mitochondria in 
the presence of Δψ. Re-translocation of the processed Pink1 to the cytosol is a prerequisite 
for a postulated model, in which Pink1-PF associates with Parkin to prevent its 
translocation to mitochondria and induction of mitophagy under steady-state conditions 
(Fedorowicz et al., 2014). In proposing a distinct function for Pink1-PF, this model 
contradicts the previous notion, that Pink1-FL is the single functional Pink1 species and 
that cleavage represents degradation rather than processing (Greene et al., 2012, Jin et al., 
2010, Matsuda et al., 2010, Narendra et al., 2010b).  
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6.5 Pink1 turnover rates are independent of the mitochondrial 
membrane potential 
Although protein turnover reactions were proposed to maintain low levels of Pink1 under 
steady-state conditions (Pickrell & Youle, 2015), the subcellular degradation site and the 
responsible proteases have not been conclusively identified so far. While the proteasome 
was shown to degrade the processed Pink1 (Lin & Kang, 2008, Yamano & Youle, 2013), 
a conflicting study suggested the matrix-resident mitochondrial protease Lon to mediate 
Pink1 turnover (Thomas et al., 2014). Moreover, a diverse set of endogenous 
mitochondrial proteases, namely MPP, PARL, ClpXP and the mitochondrial AAA 
protease have been shown to affect Pink1 stability. The proposed fast degradation was 
correlated with a Δψ-dependent import of Pink1 (Jin et al., 2010). As discussed above, 
Pink1 import was not unambiguously dependent on the presence of a Δψ in my 
experiments. Moreover, by directly assessing Pink1 degradation, I observed only moderate 
turnover rates under normal conditions, both on cellular and on mitochondrial levels. 
Remarkably, the degradation rates of Pink1 were not affected by the presence or absence 
of a Δψ. Using a similar experimental approach to measure cellular turnover of Pink, Lin 
et al. observed a stabilizing effect of Δψ-depletion on Pink1-FL (Lin & Kang, 2008). 
However, reasoning that not Pink1-FL but Pink1-PF is the major target of degradation 
(Yamano & Youle, 2013), their finding reflects a decreased processing efficiency under 
Δψ-depletion conditions, rather than an effect on degradation as such. As to my 
mitochondrial degradation assay, the failure of ATP-depletion to affect mitochondrial 
degradation of Pink virtually precludes an involvement of the collectively ATP-dependent 
mitochondrial proteases (Voos, 2013). This observation is in line with published results 
showing that both full-length and processed Pink1 accumulate at the outer face of the 
OMM independent of the Δψ (Becker et al., 2012a, Zhou et al., 2008) as this localization 
precludes degradation by mitochondrial proteases.  
 
6.6 Pink1 levels are regulated by a transcriptional mechanism 
In the experiments shown here, I observed a rather slow increase in Pink1 protein levels in 
response to mitochondrial perturbations, as Pink1 became detectable only after 4 h of 
CCCP treatment in cultured cells. This delayed accumulation was likely not due to the 
pharmacokinetics of CCCP, as an almost complete dissipation of Δψ occurs already after 
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15 min of exposing cells to the protonophore (data not shown). The observed time course 
of Pink1 accumulation is consistent with published results obtained under comparable 
experimental conditions and analyzing total cellular levels of endogenous Pink1 (Gomez-
Sanchez et al., 2014). An accumulation of Pink1 already after 0.5 h was reported 
elsewhere, but based either on immunofluorescence analysis of ectopically expressed 
Pink1 or immunodetection of endogenous Pink1 in carbonate extracts of isolated 
mitochondria (Narendra et al., 2010b). An accumulation of Pink1 in the course of hours is 
consistent with a transcriptional induction mechanism. In my thesis, I directly confirmed a 
transcriptional regulation of Pink1 levels. First, inhibitors of transcription or translation 
completely blocked damage-related mitochondrial accumulation of the protein and 
secondly Pink1 mRNA levels were elevated after induction of mitochondrial stress 
conditions. The increase in Pink1 biosynthesis together with its intrinsic targeting 
properties to the OMM is sufficient to explain the observed accumulation at damaged 
mitochondria. A complete block of Pink1 accumulation by translational inhibitors after 
depletion of Δψ was already observed in previous experiments (Narendra et al., 2010b) 
but not considered important for the downstream mitophagy pathway, due to the apparent 
absence of an increase in Pink1 mRNA levels. Several other groups reported an 
involvement of transcriptional induction in the context of a protective function of Pink1 
(Duan et al., 2014, Gomez-Sanchez et al., 2014, Priyadarshini, Orosco et al., 2013). An 
increase in Pink1 expression after cellular insults that were not specific to mitochondria 
but lead to general autophagy processes, in particular starvation and growth factor 
deprivation by serum removal (Klinkenberg, Gispert et al., 2012, Mei, Zhang et al., 2009, 
Uittenbogaard, Baxter et al., 2010) or ischemia/perfusion injury (Sakurai, Kawamura et 
al., 2009, Sengupta, Molkentin et al., 2011) was also described. Similarly, expression of 
Parkin as the immediate downstream partner of Pink1 was proposed to be under 
transcriptional control (Klinkenberg et al., 2012). These observations indicate that Pink1, 
together with Parkin, may also be involved in integrating mitophagy and cellular 
autophagy.  
 
In my experiments shown here, treatment of cells with chemicals that induce oxidative 
stress did not result in elevated protein levels of Pink1. This observation apparently 
contradicts the reported finding that diverse oxidative stress inducing compounds lead to 
elevated Pink1 mRNA levels (Murata, Takamatsu et al., 2015). However the increase in 
6 Discussion 
 
83 
Pink1 transcription described by Murata et al. occurred over the course of days, as 
opposed to the relatively fast induction of Pink1 in response to OXPHOS inhibitors I 
observed here. A long-term damage of mitochondria by oxidative stress may provoke cell-
protective autophagy reactions that may involve also Pink1 (Wang, Nartiss et al., 2012) 
but are putatively distinct from the short-term transcriptional response observed here. 
 
Previous reports also indicated a connection between ER stress and mitophagy reactions 
(Fouillet, Levet et al., 2012, Zhang, Yuan et al., 2014) by a mechanism potentially 
involving Parkin. In my hands, induction of unfolded protein stress in the ER by 
tunicamycin did not lead to an induction of Pink1 expression. This observation indicates, 
that induction of Pink1 expression represents a very specific reaction to mitochondrial 
damage. 
 
The observed transcriptional up-regulation of Pink1 expression in response to 
mitochondrial damage raises questions regarding a putative mito-nuclear signaling 
pathway and a candidate transcription factor. A study published in the course of this work, 
indicated an effect of calcium ions on Pink1 transcription (Gomez-Sanchez et al., 2014). 
However, exposure of cells to thapsigargin, which reportedly increases intracellular Ca2+-
levels (Thastrup et al., 1990), did not have any effect on Pink1 protein levels in my hands. 
Supposing that cytosolic calcium levels were indeed increased under the experimental 
conditions, this observation argues against the involvement of a calcium-responsive factor. 
Further experiments shown in the present thesis point towards an involvement of the 
NF-kB signaling pathway in Pink1 transcriptional regulation, which is in line with a recent 
report showing that the Pink1 promoter is under control of the transcription factor NF-kB 
(Duan et al., 2014). Intriguingly, calcium may come back in the focus here, as the Ca2+- 
and calmodulin-dependent phosphatase calcineurin was proposed to promote NF-kB-
signaling through dephosphorylation and inactivation of the endogenous NF-kB inhibitor 
I-kBβ (Biswas, Anandatheerthavarada et al., 2003). Notably, the diminished Pink1 
induction I observed in the presence of NF-kB inhibitors may also represent an indirect 
effect. As was previously reported, the inhibitor of another IkB isoform, I-kBa, directly 
affects the integrity of the OMM to counteract the induction of apoptosis (Pazarentzos, 
Mahul-Mellier et al., 2014). Inhibitors that affect IkB activity, as used here, could 
potentially stabilize mitochondria and may therefore indirectly reduce Pink1 induction. A 
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recent publication proposed a novel pathway whereby NF-kB positively regulates 
transcription of the autophagy adaptor p62 to mediate Parkin-dependent mitophagy in 
macrophages as part of an inflammatory response (Zhong, Umemura et al., 2016). 
Although the events upstream of Parkin in this pathway may be distinct from damage-
related mitophagy, it points towards a connection between NF-kB activity and mitophagy 
in a broader context. 
 
6.7 Revised model of Pink1/Parkin-mediated mitophagy 
The damage-induced transcriptional up-regulation of Pink, which I have demonstrated 
here calls for a revised model of Pink1/Parkin-mediated mitophagy (Figure 35). In this 
model, mitochondrial perturbations are signaled to the nuclear transcription machinery, 
where the expression of the PINK1 gene is activated. This proposed mito-nuclear 
signaling pathway putatively involves NF-kB. Upon translation at cytosolic ribosomes, the 
newly synthesized Pink1 protein associates with the outer mitochondrial membrane 
through its N-terminal mitochondrial targeting signal. Accumulation of Pink1 results in 
the recruitment and activation of Parkin, which in turn, initiates the downstream 
mitophagy pathway. The processes leading from the initial pathologic insult to 
accumulation of Pink1 may require several hours. As opposed to its previously postulated 
function in sensing mitochondrial damage by assessing Δψ, Pink1 represents a 
downstream mediator in the removal of generally damaged mitochondria by mitophagy.  
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Figure 35: Proposed model for transcriptional regulation of Pink1 protein levels.  
Different mitochondrial stress conditions generate as yet unknown mitochondria to nucleus signal, which 
induces transcription of Pink1. After translation at cytosolic ribosomes, the newly synthesized Pink1 
proteins translocate to the outer mitochondrial membrane where they initiate the downstream mitophagy 
pathway. 
 
Several signaling pathways have been identified that involve a communication between 
mitochondria and the gene expression machinery in the nucleus. In general, these 
signaling mechanisms allow adjusting the mitochondrial protein content and accordingly, 
organellar activity to different internal or external stress situations. In this context, 
mitochondria and nucleus communicate through a complex network of anterograde 
(nucleus to mitochondria) and retrograde (mitochondria to nucleus) signaling mechanisms 
(Quiros, Mottis et al., 2016). The proposed Pink1/Parkin signaling might represent a 
mammalian variant of a mitochondria-specific stress-signaling pathway. The best-studied 
example so far is the mitochondrial unfolded protein response (mtUPR) in C. elegans. 
This protective transcriptional response is triggered by mitochondrial proteotoxic stress 
and promotes the expression of mitochondrial PQC genes (Haynes, Fiorese et al., 2013). 
The transcriptional mechanism underlying the mtUPR is coordinated by the transcription 
factor ATFS-1 (activating transcription factor associated with stress 1), which is imported 
into mitochondria under normal conditions but translocates to the nucleus upon 
mitochondrial protein stress (Haynes et al., 2013). Similarly, severe mitochondrial damage 
would be signaled to the nucleus, by a yet unidentified factor and promote Pink1 
expression. 
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6.8 Association of wild-type and mutant α-synuclein with 
mitochondria 
To date, a decline in mitochondrial function is widely recognized as a feature of 
Parkinson’s disease. A pivotal question remains, if mitochondrial damage causes PD or 
rather occurs as a consequence of other pathological processes. Mutations in the genes 
encoding Pink1 and Parkin, respectively that cause hereditary PD clearly support a 
“mitochondrial hypothesis”. Considering that the initiation of mitophagy is the foremost 
function of these two proteins, a genetic defect in the Pink1/Parkin system would result in 
the accumulation of dysfunctional mitochondria as an early event in the etiology of the 
disease. By contrast, other PD-related factors may exert mitochondrial damage as part of a 
broader cellular toxicity and among them is α -synuclein. The aggregation-prone cytosolic 
protein is thought to form toxic oligomers (Haass & Selkoe, 2007). In its aggregated form, 
α -synuclein is the major constituent of intra-neuronal Lewy-body inclusions, which are 
the pathological hallmark of PD (Goedert, 2001). Mutations affecting the α-synuclein 
amino acid sequence as well as gene multiplications have been implicated in PD 
(Benskey, Perez et al., 2016). Several groups have reported the presence of α -synuclein at 
or in mitochondria (Cole, Dieuliis et al., 2008, Devi et al., 2008, Li et al., 2007, Parihar, 
Parihar et al., 2008, Shavali, Brown-Borg et al., 2008). However, these reports were 
largely controversial regarding the suborganellar localization of α-synuclein. A proposed 
interaction of α-synuclein with mitochondria is consistent with data showing 
mitochondrial abnormalities upon overexpression of wild-type or mutant α -synuclein both 
in vivo and in vitro. The reported defects include inhibition of respiratory chain complexes 
(Subramaniam, Vergnes et al., 2014) and mitochondrial fragmentation (Plotegher, Gratton 
et al., 2014). 
 
In my thesis, I directly assessed a putative interaction of α -synuclein with mitochondria 
using an in vitro import assay with isolated intact mitochondria. In this experiment, 
α-synuclein did not behave like a canonical mitochondrial imported protein. First, both 
wild-type α-synuclein as well as the two PD-related mutants A30P and A53T readily 
associated with mitochondria but the amount of mitochondria-bound α-synuclein did not 
increase over time. Secondly, α-synuclein remained largely accessible to protease 
treatment in the presence of mitochondria. Thirdly, the association of α-synuclein with 
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mitochondria occurred independent of cytosol-exposed TOM receptors but was dependent 
on the presence of an inner membrane potential. 
 
The kinetics of α-synuclein binding to mitochondria together with the observation that the 
protein did not acquire protease resistance indicate, that it was likely not imported into the 
mitochondrial matrix compartment or inserted into the IMM but rather peripherally bound 
to the outer mitochondrial membrane. Unlike the initial association of most mitochondrial 
preproteins with the OMM, this binding was independent of cytosol-exposed TOM 
receptors, which further argues against canonical import of α-synuclein. The observed 
association of α-synuclein with the OMM may reflect the general property of the protein 
to bind lipid membranes (Kim, Laurine et al., 2006). In this regard, I observed a more 
efficient binding of α-synucleinA53T, whereas less a-synucleinA30P associated with 
mitochondria compared to the wild-type protein. Both observations correlate well with 
previously reported characteristics of the two mutant forms of α-synuclein. While the 
A53T mutation has been demonstrated to enhance the membrane interacting properties of 
α -synuclein, the A30P mutation was shown to result in reduced affinity for phospholipids 
(Auluck, Caraveo et al., 2010). A general tendency of α-synuclein to bind lipids raises 
questions concerning the specificity of its association with mitochondria. In experiments 
using artificial membrane vesicles, α-synuclein was previously demonstrated to bind 
acidic lipids, including the mitochondria-specific lipid cardiolipin with a high affinity 
(Nakamura, Nemani et al., 2008). Although cardiolipin is enriched in the IMM, it is also 
found in the OMM (Hovius, Thijssen et al., 1993). Thus, the observed binding of 
α-synuclein to the OMM possibly represents an interaction with cardiolipin.  
 
In my import assay I found that the association of α -synuclein with mitochondria was 
diminished in the absence of Δψ. While this observation is in line with a previously 
reported result (Devi et al., 2008), another study came to the contradictive conclusion that 
α-synuclein binding to mitochondria does not depend on the energetic state of the 
organelle (Nakamura et al., 2008). Notably, the initial association of authentic 
mitochondrial preproteins with import receptors of the OMM and the insertion into the 
TOM channel occurs independent of the membrane potential. The only Δψ-dependent step 
in the canonical presequence import pathway is the translocation of the preprotein over- or 
its insertion into the IMM, respectively (Becker et al., 2012b). However, the α-synuclein 
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sequence lacks a mitochondrial targeting signal (Guardia-Laguarta et al., 2014) and my 
results strongly suggest that the protein was not imported into any internal mitochondrial 
subcompartment. Thus, dependency on Δψ was not indicative of import into the matrix 
compartment or IMM here, but rather reflected a characteristic of the interaction between 
α-synuclein and the OMM. One plausible explanation for an effect of Δψ would be an 
altered lipid composition of the OMM upon mitochondrial depolarization. Similarly, 
exposure of cardiolipin in response to cytosolic acidification has been proposed to 
facilitate α-synuclein binding to the OMM (Cole et al., 2008). 
 
Further elucidating the observation that α -synuclein did not behave like a canonical 
mitochondrial-targeted protein in my import assay, Guardia-Laguarta et al. proposed an 
alternative model for α -synuclein interaction with mitochondria (Guardia-Laguarta et al., 
2014). In fractionation assays with total cellular extracts, wild-type and mutant forms of 
the protein were shown to localize not to mitochondria but rather to so-called 
mitochondria-associated ER membranes (MAM). These structurally and functionally 
distinct ER subdomains were previously proposed to facilitate the cooperation between 
ER and mitochondria in various joint processes, including Ca2+ homeostasis, phospholipid 
biosynthesis and intracellular trafficking (Paillusson et al., 2016). Guardia-Laguarta et al. 
further showed that the pathogenic mutations A30T and A53P reduced α-synuclein 
localization to MAM. Diminished amounts of α-synuclein in MAM coincided with an 
increased spatial distance between ER and mitochondria and mitochondrial fragmentation 
(Guardia-Laguarta et al., 2014). While the details still need to be worked out, the proposed 
interaction of α-synuclein with MAM may provide a mechanism whereby α-synuclein 
affects mitochondrial function in PD. The described interaction of α-synuclein with MAM 
would explain the apparent association with mitochondria I observed in the in vitro import 
assay, provided that the crude mitochondrial fractions used for this experiment contained 
mitochondria-associated ER membranes. It will further be interesting, to revisit the effect 
of Δψ on α-synuclein binding observed in my import assay in the light of the proposed 
association of the protein with MAM. One possibility is that mitochondrial depolarization 
destabilizes the mitochondria-ER contacts, which would result in reduced binding sites for 
α-synuclein.  
 
6 Discussion 
 
89 
In light of the Pink1 experiments shown here, α-synuclein is of particular interest as it 
represents a potential mediator of mitochondrial damage with a direct relevance for PD. 
Considering the implication of both α-synuclein and the Pink1/Parkin system in PD, a 
possible connection between them is scarcely described so far. In Drosophila models, 
Pink1 and Parkin can rescue the mitochondrial fragmentation phenotype induced by 
overexpression of α-synuclein (Kamp 2010). It remains to be clarified, if vise versa, 
elevated levels of α-synuclein elicit Pink1 accumulation and mitophagy.  
 
In conclusion, genetic and biochemical findings on the Pink1/Parkin system, α-synuclein 
and other genetic risk factors have impressively advanced PD research over the last years. 
Yet, a lot of work remains to be done. My own results may exemplify this complexity on 
the small scale. While the proposed transcriptional regulation of Pink1 may help 
reconsidering the events leading to the initiation of mitophagy, the underlying signaling 
mechanism still awaits identification. It should be kept in mind that our present knowledge 
on the pathology of PD stems from studying the small percentage of hereditary cases. 
Thus, a major leap in PD research will require translating the gathered information to 
sporadic forms of the disease. In parts, this transition has already started as illustrated by a 
recent paper examining the mechanism whereby a single nucleotide polymorphism (SNP) 
within the α-synuclein-encoding gene SNCA increases the risk of developing sporadic PD 
(Soldner, Stelzer et al., 2016). The authors propose that a certain sequence variant reduces 
the binding of inhibitory transcription factors, which results in elevated SNCA expression. 
Intriguingly the described gene variant has a much higher prevalence compared to rare 
point mutations in SNCA. From the mitochondrial point of view, a major question remains 
how, α-synuclein-mediated toxicity, age-related mitochondrial dysfunction and organellar 
quality control collectively contribute to the pathology of PD. 
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7 Abstract 
Mitochondrial dysfunction is a common feature of many neurodegenerative diseases, in 
particular Parkinson’s disease (PD). Mutations in the genes encoding the mitochondrial 
kinase Pink1 and the cytosolic E3 ubiquitin ligase Parkin have been associated with 
familial cases of PD. In healthy cells, the Pink1/Parkin system functions as sensor of 
mitochondrial damage in an organellar quality control system. High levels of Pink1 
accumulate at the surface of damaged mitochondria to recruit and activate Parkin. In turn, 
Parkin initiates a signaling reaction eventually resulting in the autophagic removal of the 
organelle, a process termed mitophagy. 
 
In my thesis, I analyzed mitochondrial and cellular stress conditions, resulting in an 
increase in Pink1 protein levels. I was able to demonstrate that the accumulation of Pink1 
was not strictly correlated with a depolarization of the mitochondrial inner membrane 
potential (Δψ) or with changes in mitochondrial ATP levels. Both cellular and 
mitochondrial protein turnover rates were also not affected by changes in the 
mitochondrial membrane potential. In contrast, inhibition of cellular transcription or 
translation reactions completely blocked Pink1 accumulation. Characterization of mRNA 
levels indicated that the increase of Pink1 amounts after acute mitochondrial perturbations 
was based on a transcriptional induction reaction. My results demonstrate that the 
mitochondrial quality control process mediated by the Pink1-Parkin system is based on a 
transcriptional response triggered independently of reductions in Dy. This yet unknown 
signaling pathway may involve the transcriptional regulator NFκB. Another factor 
prominently involved in PD is the aggregation-prone cytosolic protein α-synuclein, which 
is the major constituent of Lewy body inclusions. Although α-synuclein has previously 
been proposed to exert mitochondrial damage and localize to mitochondria, its 
submitochondrial localization remained controversial. In my thesis, I was able to 
demonstrate that α-synuclein is not imported into mitochondria but apparently associates 
with the outer mitochondrial membrane in a Δψ-dependent manner.  
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8 Abbreviations 
 
35S Sulfur isotope with mass number 35 
AA Antimycin A 
AD Autosomal dominant 
AR Autosomal recessive 
ATP Adenosine triphosphate 
BN Blue native  
BSA Bovine serum albumin 
C-terminus Carboxy-terminus 
CCCP Carbonyl cyanide m-chlorophenyl hydrazone 
Chx Cycloheximide 
CMV Cytomegalovirus 
COX Cytochrome c oxidase 
DHFR Dihydrofolate reductase 
DMSO Dimethyl sulfoxide 
DNA Deoxy-ribonucleid acid 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmatic reticulum 
EtOH Ethanol 
FCS Fetal calf serum 
FL Full-length 
FLAG Octapeptide protein tag  
g Gravity 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green fluorescent protein 
Hsp Heat shock protein 
IgG Immunoglobulin G 
IKK IkB kinase 
IMM Inner mitochondrial membrane 
IMS Intramembrane space 
IkB Inhibitor of NF-kB 
kd Knock-down 
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kDa Kilodalton 
Lys Lysine 
MAM Mitochondria-associated ER membranes 
Mdh2 Malate dehydrogenase 
MEF Mouse embryonic fibroblasts 
Mfn Mitofusin 
min Minute 
mM Millimolar 
MPP Matrix processing peptidase 
Mr Relative molecular mass 
mRNA Messenger RNA 
N-terminus Amino-terminus 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B-cells 
nm Nanometer 
nM Nanomolar 
Oligo Oligomycin 
OMM Outer mitochondrial membrane 
OXPHOS Oxidative phosphorylation 
PAGE Polyacrylamide gel electrophoresis 
PD Parkinson’s disease 
PF Processed form 
Pink1 PTEN-induced putative kinase 1 
PK Proteinase K 
PQC Protein quality control 
PTEN Phosphatase and tensin homolog 
qRT-PCR Quantitative real-time polymerase chain reaction 
RING Really interesting new gene domain 
RNA Ribonucleic acid 
SDH Succinate dehydrogenase 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
siRNA small interfering RNA 
SU9 Subunit 9 of mitochondrial ATPase 
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TCA Trichloroacetic acid 
TIM Translocase of the inner (mitochondrial) membrane 
TMRE Tetramethylrhodamine ethyl ester 
TOM Translocase of the outer (mitochondrial) membrane 
Ub Ubiquitin 
WT Wild-type 
α-Tom40 Antibody directed against Tom40 
Δψ Mitochondrial membrane potential 
µM Micromolar 
 
9 Appendix 
 
 
Figure 36: Schematic illustration of DHFR fusion proteins and the SU9-GFP control construct. The 
first 70 aa of N.crassa ATPase subunit 9 (SU9(70)) are fused to green fluorescent protein (GFP) alone or 
GFP followed by the full mouse dihydrofolate reductase (DHFR). Asterisks indicate the three point 
mutations in the destabilized DHFR (DHFRds) C7S, S42C, N49C, respectively. The cleavage site for the 
mitochondrial processing peptidase (MPP) within the SU9 sequence is indicated.  
 
 
Figure 37: Schematic illustration of the Parkin domain structure. The N-terminal ubiquitin-like (Ubl) 
domain is followed by RING0 and a RING1 In-between RING2 (RBR) motif. IBR: In between RING. 
RING: Really interesting new gene domain. 
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